## **Obesity paradox in patients with cancer:**

# A systematic review and meta-analysis of 6,320,365 patients

Fausto Petrelli<sup>1</sup>, Alessio Cortellini<sup>2</sup>, Alice Indini<sup>3</sup>, Gianluca Tomasello<sup>4</sup>, Michele Ghidini<sup>3</sup>, Olga Nigro<sup>5</sup>, Massimiliano Salati<sup>6</sup>, Lorenzo Dottorini<sup>7</sup>, Alessandro Iaculli<sup>7</sup>, Antonio Varricchio<sup>8</sup>, Valentina Rampulla<sup>8</sup>, Sandro Barni<sup>1</sup>, Mary Cabiddu<sup>1</sup>, Antonio Bossi<sup>9</sup>, Antonio Ghidini<sup>10</sup> and Alberto Zaniboni<sup>11</sup>

## Obesity paradox in cancer patients

- 1: Oncology unit, ASST Bergamo ovest, Treviglio (BG), Italy
- 2: Oncology unit, San Salvatore hospital, L'Aquila, Italy; Department of biotechnology and applied clinical sciences, University of L'Aquila, L'Aquila, Italy
- 3: Oncology unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
- 4: Oncology unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
- 5: Oncology unit, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
- 6: Oncology unit, University Hospital of Modena, Modena Cancer Centre, Modena, Italy
- 7: Oncology unit, ASST Bergamo est, Seriate (BG), Italy
- 8: Surgical oncology unit, ASST Bergamo ovest, Treviglio (BG), Italy
- Endocrine Diseases Unit-Diabetes regional center, ASST Bergamo Ovest, Treviglio
   (BG), Italia
- 10: Oncology unit, Casa di cura Igea, Milano, Italy
- 11: Oncology unit, Fondazione Poliambulanza, Brescia, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Word count: 2637

# **Corresponding author:**

Dr. Fausto Petrelli: Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest,

Piazzale Ospedale 1, 24047, Treviglio (BG) Italy

Tel. +390363424420

Fax +390363424380

Email: faupe@libero.it

#### **Abstract**

**BACKGROUND.** Obesity, defined as a body mass index (BMI)  $\geq$  30 kg/m2, is associated with a significant increase in risk of many cancers. In last years, various studies suggested that obese cancer patients have better outcomes than non-obese patients. This phenomenon, also known as "the obesity paradox", is not well understood and presents controversial explanations. We performed a systematic review and meta-analysis to assess the association between obesity and outcome after a diagnosis of cancer.

**PATIENTS AND METHODS.** PubMed, the Cochrane Library, and EMBASE were searched from inception to January 2020, for studies reporting prognosis of patients with obesity and cancer. Risk of death, cancer-specific survival (CSS) and progression were pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI). The primary outcome of the study refers to overall survival (OS) in obese vs non-obese patients with malignancies. Secondary endpoints were CSS and progression- or disease-free survival (PFS or RFS).

**RESULTS**. Mortality and relapse associated with obesity in patients with cancer were evaluated among n=6,320,365 participants (n=203 studies). Overall, association of obesity and cancer was associated with a reduced OS (HR =1.14, 95% CI: 1.09–1.19; P<.01) and CSS (HR=1.17, 95%CI 1.12-1.23; P<.01). Patients were also at increased risk for relapse (HR=1.13, 95%CI 1.07-1.19; P<.01). Patients with breast, colorectal and uterine tumors were at increased risk of death. Conversely, obese with lung cancer, renal cell carcinoma and melanoma survived longer that non-obese.

**CONCLUSIONS.** In many cancer patients, obesity reduces survival and increases the risk of relapse. In lung cancer, renal cell carcinoma and melanoma obesity was protective in terms of outcome. More intensive follow up, adequate dosing of oncological treatments, calories intake restrictions, physical activity and monitoring of obesity-related complications are effective measures for reducing mortality in these subjects.

**Keywords:** obesity, cancer, survival, meta-analysis

#### Introduction

Obesity, defined as a body mass index (BMI) greater than 30 kg/m2, is a chronic disease with an increasing prevalence around the world, largely contributing to important health issues in most countries. Despite body fat is a general risk factor for serious illness (e.g. metabolic syndrome), greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic deposits<sup>1</sup>. Several large epidemiologic studies have evaluated the link between obesity and mortality. In particular, a meta-analysis of 230 cohort studies including over 30 million individuals, found that both obesity and overweight were associated with an increased risk of all-cause mortality<sup>2</sup>. Despite the evidence that excess mortality increases with increasing BMI, some studies have reached the conclusion that elevated BMI may improve survival in subjects with cardiovascular disease, a phenomenon called the "obesity paradox"<sup>3</sup>.

Increased BMI is also associated with an increased risk of multiple cancer types<sup>4</sup>. In addition, obesity and overweight may increase cancer mortality<sup>5</sup>. During last decades we also observed a more rapid increase in obesity among adult cancer survivors compared with the general population<sup>6</sup>. The mechanisms contributing to higher cancer incidence and mortality may include alterations in sex hormone metabolism, insulin and insulin-like growth factor levels, and adipokine pathways<sup>78</sup>.

In last years, various studies suggested that, in cancers, patients with a normal BMI have worse outcomes than obese patients. This phenomenon (the obesity paradox) in cancer, is not well understood and presents controversial explanations<sup>91011</sup>. Three different meta-

analyses led to different results in particular in lung and renal cell carcinomas<sup>121314</sup>. In lung cancer, obesity has favourable effects on long-term survival of surgical patients. Moreover, in renal cell carcinoma an inconsistent effect of BMI on cancer-specific survival was found. Conversely, breast, ovarian and colorectal cancer are invariably associated with increased mortality in obese patients<sup>151617</sup>. The main explanations proposed to answer these observations include the general poor health status of patients with very low BMI. Additionally, weight loss may usually be associated with frailty and other risk factors (e.g. smoke)<sup>10</sup>. In cancer, obesity is also associated with increased efficacy of PD-1/PD-L1 blockade in both tumor-bearing mice and patients<sup>11</sup>.

This updated systematic review and meta-analysis was conducted to evaluate the prognosis of obese vs non-obese cancer patients.

#### **Material and methods**

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines<sup>1819</sup>.

#### Search strategy and inclusion criteria

A systematic search was conducted of the EMBASE, Pubmed and The Cochrane Library published from inception until January 2020. The following search terms were used: ((carcinoma or cancer or sarcoma or melanoma or ("Neoplasms"[Mesh])) AND (obese OR obesity OR 30 kg/m² OR "body mass index") AND (hazard ratio) AND survival AND (multivariate OR cox). The reference lists of identified articles were then manually searched to identify potentially relevant omitted citations. Articles that were not published in the English language were not included in this study.

Retrospective and observational studies (cohort, case control) or prospective trials were selected when they reported the association of obesity, defined as a BMI ≥30 kg/m2, with the risk of death (OS), cancer-specific death (CSS) or disease-progression (PFS or DFS) in patients with cancer. We placed no restrictions on study setting, size, race or country. The inclusion was limited to studies reporting hazard ratios (HRs) and their corresponding 95% CIs. Studies were restricted to adult patients with solid tumors. Hematologic malignancies were excluded.

The most up-to-date versions of full-text publications were included. Study selection was performed in 2 stages, first, titles and abstracts were screened; then, selected full-text articles were included according to the eligibility criteria. Screening was performed independently by 10 authors (MG, GT, AG, AI, AC, ON, VR, AI, LD, MS) and conflicts were handled by consensus with a senior author (FP).

#### Data Collection and quality assessment

Data were collected independently by using a predesigned spreadsheet (Excel [Microsoft]. Collected data items included authors, year of publication, study setting and design, median follow up, treatments received, outcomes, and type of analysis. The primary outcome was OS, secondary endpoints were CSS and PFS/DFS. Along with data extraction, 1 author (FP) assessed study quality according to a modified Newcastle Ottawa Scale<sup>20</sup>.

#### Statistical analysis

First, pooled HRs with 95% CIs were estimated using random effects meta-analysis with the generic inverse-variance method for studies that provided fully adjusted HRs.

Inconsistency across studies was measured with the I2 method. Cutoff values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. When I2

was larger than 50%, a random effects model was used; otherwise, the fixed effects model was used. Second, to examine heterogeneity, we performed analyses of predefined subgroups based on type of disease. Additionally, to address potential bias and verify our results, we performed sensitivity analysis using a leave-one-out method and the Trim and Fill method. Finally, to investigate the risk of publication bias, we applied the Egger test and visually inspected the funnel plots (begg's test). All analyses were carried out using Comprehensive Meta-Analysis software,

### Results

Our literature search yielded 1,892 articles, of which 203 met the inclusion criteria for our overall systematic review of the effect of obesity on cancer outcome<sup>21,22,31,121–130,32,131–140,33,141–150,34,151–160,35,161–170,36,171–180,37,181–190,38,191–200,39,201–210,40,211–220,23,41,221–223,42–50,24,51–60,25,61–70,26,71–80,27,81–90,28,91–100,29,101–110,30,111–120 (Fig. 1). Most excluded studies did not use the cut-off value for obesity (BMI values different from 30 kg/m2) or used different cut-off for risk of death (e.g. 1 kg/m2 of increase in BMI). Of the 203 articles, 170 were eligible for inclusion in the systematic review of the risk of obesity with OS, 109 for correlation with CSS, and 79 for correlation with DFS/PFS. Descriptive data for studies included in our meta-analysis are listed in Table 1. Overall, the included studies encompassed a total of 6,320,365 patients. Sample sizes ranged from 41 to 1,096,492 with a median of 1,543. Most studies were retrospective in nature (n=132), the minority were prospective cohort/observational studies (n=63) or pooled analysis/randomized trials (n=8).</sup>

#### Overall survival and obesity in cancer patients

N=170 studies reported data on OS. Because the heterogeneity test showed a high level of heterogeneity ( $I^2 = 79.7\%$ , P<.01) among studies, a random-effects model was used for the analysis. OS of obese patients was significantly worse (HR =1.14, 95% CI: 1.09–1.19; P<01; Figure 2) compared to those of not obese patients.

Cancer-specific survival and obesity in cancer patients

Similarly, obesity reduced CSS in n=109 studies (HR=1.17, 95%CI 1.12-1.23; P<.01; Figure 3), which reported data on cancer mortality. Heterogeneity was high (I<sup>2</sup>=73.9%), so a random effect model was used

Progression-free survival and obesity in cancer patients

Obese patients with cancer (n=79 studies) have a worse DFS/PFS than non-obese subjects (HR=1.13, 95%CI 1.07-1.19; P<0.01). Heterogeneity was high (I<sup>2</sup>=73.7%), so a random effect model was used.

Subgroup analysis

A subgroup analysis for OS was performed according to type of disease (Suppl. file 1), type of study (retrospective vs prospective: HR=1.07, 95%CI 1.07-1.18, P<.01 vs HR=1.14, 95%CI 1.05-1.23, P<.01), duration of follow up (> vs < 10 years HR=1.16, 95%CI 0.86-1.58, P=.08 vs HR=1.23, 95%CI 0.84-3; P=.09), race (Non asiatic HR= 1.22, 95%CI 0.86-1.6, P=.06 vs HR=1.22, 0.74-1.72, P=.09) and stage of disease (early vs advanced: HR=1.20, 95%CI 0.99-1.25, P=.072 vs HR=1.2, 95% 1.12-1.28, P=.01).

**Publication bias** 

A funnel plot was used to assess publication bias in the studies evaluating OS in obese versus not obese cancer patients. No publication bias was detected (Begg's test P=.23). Egger's test was instead significant (P=0.03) (Suppl. file 2). According to the Trim and Fill method n=18 studies were placed to the left of the mean, and according the random effect model the final result was similar (HR=1.08, 95%CI 1.03-1.13). After the one study removed procedure the HR for ranged from 1.14 to 1.15.

8

**Discussion** 

This meta-analysis of published (observational and retrospective) studies shows that overall mortality is increased in obese patients with breast, colorectal and uterine cancers. Cancer mortality is increased in breast, colorectal, prostate and pancreatic cancers. Finally, relapse rate is increased in breast, colorectal, prostate and gastroesophageal cancers. The "obesity paradox", that means the apparent better cancer mortality in obese patients, is observed in lung cancer and in melanoma, despite these data derive from n=12 studies only.

Various factors are potentially linked to increased cancer mortality in some malignancies. Hormonal factors, reduced physical activity, more lethal/aggressive disease behavior, metabolic syndrome and a potential undertreatment in obese subjects are possible reasons. It is well known that postmenopausal women with higher BMI have an increased breast cancer risk due to higher estrogen levels resulting from the peripheral conversion of estrogen precursors (from adipose tissue) to estrogen<sup>224</sup>. In these patients weight loss and exercise may reduce cancer risk through lowering exposure to breast cancer biomarkers<sup>225</sup>. In colorectal cancer, BMI before diagnosis was associated with increased all-cause, cardiovascular and colorectal cancer specific mortality<sup>226</sup>. The reason of this association is presently not completely understood although insulin, insulin-like growth factors, their binding proteins, chronic inflammation, oxidative stress, and impaired immune surveillance have been supposed to be causative factors<sup>227</sup>. In pancreatic cancer higher prediagnostic BMI was associated with more advanced stage at diagnosis, with 72.5% of obese patients presenting with metastatic disease versus 59.4% of healthyweight patients (P = .02) in 2 large prospective cohort studies<sup>222</sup>. Lastly, in prostate cancer obesity may a consequence of androgen deprivation therapy but seems also related with more aggressive disease (i.e., Gleason score ≥7)<sup>228</sup> or more advanced disease at diagnosis<sup>229</sup>.

Our results showed that obese lung cancer patients had significantly prolonged cancer specific survival and overall survival compared to non-obese patients. When considering these findings, we must take into account that 9 out of 11 evaluated studies included advanced/metastatic patients. Cancer cachexia mechanisms are not completely defined yet, but several evidences showed that the systemic inflammatory status induced either by the tumor and host-response is a key moment in its developing<sup>230</sup>. Lung cancers are indeed known to be aggressive diseases, and advanced patients are usually accompanied by poorer performance status and significant weight loss at the time of diagnosis, which underlies a systemic inflammatory response<sup>231</sup>. According to this view, a post-hoc analysis from three international phase III studies including advanced non-small cell lung cancer patients who received a platinum-based, first-line chemotherapy, revealed that weight gain during treatment was significantly associated with better clinical outcomes<sup>232</sup>. Intriguingly, a recent study showed that a decrease in BMI at lung cancer diagnosis (from the early adulthood) is a consistent marker of poor survival<sup>183</sup>. Considering these observations, an increased BMI might be considered a protective feature and potentially a marker of functional reserve for lung cancer patients. Recent evidences suggest a positive predictive role of an increased BMI for cancer patients receiving immune checkpoint inhibitors across different malignancies, including lung cancer<sup>54</sup>. Interestingly, the only study with lung cancer patients who received an immune checkpoint inhibitor (atezolizumab), revealed that the OS benefit for obese patients was significantly higher within the atezolizumabtreated cohort, compared to the doxetaxel treated cohort<sup>110</sup>. However, we have to remark that no significant OS difference was found across BMI categories within the docetaxel treated patients. Similar mechanisms can be applied to the finding of a survival benefit for obese melanoma patients from the single included study. Several evidences indeed confirmed that a high BMI might be considered a surrogate marker of clinical benefit from immune checkpoint inhibitors for advanced melanoma patients<sup>233234</sup>.

Interestingly, also obese RCC patients revealed to have a significantly longer OS compared to the respective non-obese cohorts. It has been already hypotesized that the perinephric white adipose tissue act as a reservoir of activated immune cells with increased characteristics of hypoxia, infiltration of Th1 cells, regulatory T cells, dendritic cells, and type 1 macrophages. However, only one out of six studies inclued patient receiving immunotherapy<sup>235236</sup>.

Intriguingly, we found that the association between obesity and better clinical outcomes seems to be confirmed for those malignancies in which immune checkpoint inhibitors have first (and strongly) proved to be effective, despite studies involving patients receiving immune checkpoint inhibitors are poorly represented in this meta-analysis. Such results, might probably be an epiphenomenon, however we are allowed to speculate that the white adipose tissue could be considered an immune organ, which somehow plays a role in the anti-tumor immune response. It has been observed that the adipocyte-derived hormone leptin could alter T-cell function, resulting in improved response to anti-PD-1 therapy<sup>11</sup>. Moreover, another preclinical study reported that white adipose tissue acts as a reservoir for a peculiar population of memory T cells, which elicitate some effective responses in case of antigenic re-exposure during infections (and why not in case of exposure to cancer-specific antigens?)<sup>237</sup>.

Obese patients are also at increased risk of reduced physical activity. Various studies highlighted this concept. Physical activity declines over time in obese patients<sup>238239</sup>. In particular, physical activity is strictly correlated with breast cancer and colorectal cancer mortality<sup>240241</sup>. Therefore physical (in)activity should be a major target of obesity prevention and treatment in particular in cancer patients. Type 2 diabetes mellitus is strongly associated with obesity in the metabolic syndrome. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related

deaths. The association between BMI and cause-specific mortality was also illustrated in the Prospective Studies Collaboration analysis<sup>242</sup>. In the upper BMI range (25 to 50 kg/m²), each 5 kg/m² increase in BMI was associated with a significant increase in mortality from coronary heart disease (CHD), stroke, diabetes mellitus, chronic kidney disease, and many cancers. In the same analysis, subjects with BMI below 22.5 kg/m² had higher mortality compared with subjects with a BMI of 22.5 to 25 kg/m². The excess mortality was predominantly due to smoking-related diseases (respiratory and cancer). Despite there are no clear recommendation about dosing of chemotherapy in obese patients, caution is recommended for high risk regimens<sup>243</sup>. The hypothesis that a reduced dose according to ideal body weight may lead to a reduced outcome cannot be confirmed by prospective studies but may be considered as potential reason for the observed results in some settings (e.g. breast cancer). In a pooled analysis of toxicity in obese vs non-obese rates of toxic effects were similar or lower in obese patients<sup>244</sup>.

However, this meta-analysis has several limitations. First, we combined data of obese patients and compared prognosis with different non-obese subjects (normal weight or normal weight + overweight). Second, accurate measures of weight and height are always a challenge in observational studies. The evaluation is often before diagnosis but in some studies timing of obesity diagnosis is not described. Obese subjects have a general poor prognosis in term of overall mortality and non-cancer mortality, so it seems obvious that their prognosis is dismal. However, almost all studies provided a multivariate analysis according to main prognostic factor for oncological outcome so that obesity remain generally an independent prognostic factor in cancer patients. Duration of follow up, treatments received, and countries are heterogeneous even if subgroup analysis does not explain results with these different variables. Lastly, this meta-analysis compared mortality

between patients belonging to a fixed category of obesity (>30 kg/m²) and thus we are not able to provide effect size per unit increment of kg/m².

In conclusion, results of this meta-analysis confirm and reinforce the notion that obesity is a competing risk factor for overall and cancer specific mortality and relapse in various cancers treated with curative intent or for metastatic disease except for lung cancer and melanoma where it has an apparent protective effect (obesity paradox). It is advised that in the future, oncologists increase their efforts to manage patients into multidisciplinary teams for care and cure of both cancer and obesity. Improving lifestyle (e.g., physical activity, calories intake, care/prevention of cardiovascular complications), more intensive follow-ups of cancer in obese, and adequate dose of medical therapies are all proved measures that may improve prognosis of obese cancer patients.

#### References

- Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism.* 2019. doi:10.1016/j.metabol.2018.09.005
- 2. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: Systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. *BMJ*. 2016. doi:10.1136/bmj.i2156
- 3. Lavie CJ, Sharma A, Alpert MA, et al. Update on Obesity and Obesity Paradox in Heart Failure. *Prog Cardiovasc Dis.* 2016. doi:10.1016/j.pcad.2015.12.003
- 4. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. *BMC Public Health*. 2009. doi:10.1186/1471-2458-9-88
- 5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. *N Engl J Med*.

- 2003. doi:10.1056/NEJMoa021423
- Greenlee H, Shi Z, Sardo Molmenti CL, Rundle A, Tsai WY. Trends in obesity
  prevalence in adults with a history of cancer: Results from the US National Health
  Interview Survey, 1997 to 2014. *J Clin Oncol.* 2016. doi:10.1200/JCO.2016.66.4391
- 7. Gallagher EJ, LeRoith D. Obesity and diabetes: The increased risk of cancer and cancer-related mortality. *Physiol Rev.* 2015. doi:10.1152/physrev.00030.2014
- 8. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer*. 2011. doi:10.1038/nrc3174
- 9. Lennon H, Sperrin M, Badrick E, Renehan AG. The Obesity Paradox in Cancer: a Review. *Curr Oncol Rep.* 2016. doi:10.1007/s11912-016-0539-4
- Shachar SS, Williams GR. The obesity paradox in cancer-moving beyond BMI.
   Cancer Epidemiol Biomarkers Prev. 2017. doi:10.1158/1055-9965.EPI-16-0439
- Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. *Nat Med.* 2019. doi:10.1038/s41591-018-0221-5
- 12. Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: Does the "obesity paradox" really exist? *Eur J Cardio-thoracic Surg.* 2017. doi:10.1093/ejcts/ezw386
- 13. Bagheri M, Speakman JR, Shemirani F, Djafarian K. Renal cell carcinoma survival and body mass index: A dose-response meta-analysis reveals another potential paradox within a paradox. *Int J Obes.* 2016. doi:10.1038/ijo.2016.171
- 14. Shen N, Fu P, Cui B, Bu C-Y, Bi J-W. Associations between body mass index and the risk of mortality from lung cancer: A dose-response PRISMA-compliant meta-

- analysis of prospective cohort studies. *Med.* 2017.
- 15. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies.

  Ann Oncol. 2014. doi:10.1093/annonc/mdu042
- 16. Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies.

  Cancer Causes Control. 2014. doi:10.1007/s10552-014-0450-y
- Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. *Cancer Prev Res.* 2012. doi:10.1158/1940-6207.CAPR-12-0048
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: *Journal of Clinical Epidemiology*. Vol 62.; 2009:e1-34. doi:10.1016/j.jclinepi.2009.06.006
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D,
   Becker BJ, Sipe TA TS. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology
   (MOOSE) group. JAMA. 2010;283(15):2008-2012. doi:10.1001/jama.283.15.2008
- 20. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
  http://www.ohri.ca/programs/clinical{\_}epidemiology/oxford.asp. Accessed 13 Aug
  2014. Ottawa Hosp Res Inst. 2014.
- 21. Abdel-Rahman O. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. *Expert Rev Respir*

- Med. 2019;13(10):1029-1035. doi:10.1080/17476348.2019.1656532
- 22. Abdullah A, Wolfe R, Stoelwinder JU, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. *Int J Epidemiol*. 2011;40(4):985-996. doi:10.1093/ije/dyr018
- 23. Abrahamson PE, Gammon MD, Lund MJ, et al. General and abdominal obesity and survival among young women with breast cancer. *Cancer Epidemiol Biomarkers*Prev. 2006;15(10):1871-1877. doi:10.1158/1055-9965.EPI-06-0356
- 24. Abubakar M, Sung H, Bcr D, et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. *Breast Cancer Res.* 2018;20(1):1-14. doi:10.1186/s13058-018-1033-8
- Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB.
   Impact of body mass index on clinical outcomes in triple-negative breast cancer.
   Cancer. 2011;117(18):4132-4140. doi:10.1002/cncr.26019
- 26. Akinyemiju T, Moore JX, Pisu M, et al. Mortality among Blacks and Whites. 2018;26(1):193-201. doi:10.1002/oby.22067.A
- 27. Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelines and survival after breast cancer: Findings from the after breast cancer pooling project.
  Breast Cancer Res Treat. 2012. doi:10.1007/s10549-011-1770-1
- 28. Aldrich MC, Grogan EL, Munro HM, Signorello LB, Blot WJ. Stage-adjusted lung cancer survival does not differ between low-income blacks and whites. *J Thorac Oncol.* 2013;8(10):1248-1254. doi:10.1097/JTO.0b013e3182a406f6
- 29. Alsaker MDK, Opdahl S, Åsvold BO, Romundstad PR, Vatten LJ. The association of

- reproductive factors and breastfeeding with long term survival from breast cancer. *Breast Cancer Res Treat.* 2011;130(1):175-182. doi:10.1007/s10549-011-1566-3
- 30. Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, et al. Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. *Breast Cancer Res Treat*. 2014;146(1):183-188. doi:10.1007/s10549-014-2977-8
- 31. Arem H, Park Y, Pelser C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. *J Natl Cancer Inst*. 2013;105(5):342-349. doi:10.1093/jnci/djs530
- 32. Ata N, Ayloo S, Tsung A, Molinari M. Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States. *Hpb*. 2019;21(1):67-76. doi:10.1016/j.hpb.2018.06.1797
- Bandera E V., Lee VS, Rodriguez-Rodriguez L, Bethan Powell C, Kushi LH. Impact
  of chemotherapy dosing on ovarian cancer survival according to body mass index.
   JAMA Oncol. 2015;1(6):737-745. doi:10.1001/jamaoncol.2015.1796
- 34. Hung CY, Lai CC, Chen PT, et al. Impact of body mass index on long-term survival outcome in Asian populations with solid cancer who underwent curative-intent surgery: A six-year multicenter observational cohort study. J Cancer. 2018;9(18):3316-3325. doi:10.7150/jca.25729
- 35. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. *Int J Cancer*. 2012;131(7):1711-1719. doi:10.1002/ijc.27414
- 36. Blair CK, Wiggins CL, Nibbe AM, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. *npj Breast Cancer*. 2019;5(1):1-7. doi:10.1038/s41523-019-0128-4

- 37. Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. *N Engl J Med.* 2011;365(10):901-908. doi:10.1056/NEJMoa1104119
- 38. Bonn SE, Wiklund F, Sjölander A, et al. Body mass index and weight change in men with prostate cancer: Progression and mortality. *Cancer Causes Control*. 2014;25(8):933-943. doi:10.1007/s10552-014-0393-3
- 39. Boyle T, Fritschi L, Platell C, Heyworth J. Lifestyle factors associated with survival after colorectal cancer diagnosis. *Br J Cancer*. 2013;109(3):814-822. doi:10.1038/bjc.2013.310
- Braithwaite D, Satariano WA, Sternfeld B, et al. Long-term prognostic role of functional limitations among women with breast cancer. *J Natl Cancer Inst*. 2010;102(19):1468-1477. doi:10.1093/jnci/djq344
- 41. Clark W, Siegel EM, Chen YA, et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg. 2013. doi:10.1016/j.jamcollsurg.2013.01.007
- 42. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012. doi:10.1007/s10552-012-9989-7
- 43. Caan BJ, Kwan ML. Pre-diagnosis body mass index, post-diagnosis weight change. 2010;19(10):1319-1328. doi:10.1007/s10552-008-9203-0.Pre-diagnosis
- 44. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. *Cancer Epidemiol Biomarkers Prev.* 2015;24(8):1229-1238.

- doi:10.1158/1055-9965.EPI-15-0094
- 45. Carr BI, Giannelli G, Guerra V, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. *Int J Biol Markers*. 2018;33(4):423-431. doi:10.1177/1724600818776838
- 46. Cecchini RS, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev. 2016;25(1):51-59. doi:10.1158/1055-9965.EPI-15-0334-T
- 47. Cespedes Feliciano EM, Kwan ML, Kushi LH, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. *Cancer.* 2017;123(13):2535-2542. doi:10.1002/cncr.30637
- 48. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival:

  The role of obesity and menopausal status at diagnosis. *Breast Cancer Res Treat*.

  2000;64(2):157-163. doi:10.1023/A:1006489100283
- 49. Chen X, Lu W, Zheng W, et al. Obesity and weight change in relation to breast cancer survival. *Breast Cancer Res Treat*. 2010;122(3):823-833. doi:10.1007/s10549-009-0708-3
- Chromecki TF, Cha EK, Fajkovic H, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int*. 2013;111(2):249-255. doi:10.1111/j.1464-410X.2012.11322.x
- 51. Chung IY, Lee JW, Lee JS, et al. Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. *PLoS One*. 2017;12(3):1-11. doi:10.1371/journal.pone.0170311

- 52. Connor AE, Visvanathan K, Baumgartner KB, et al. Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study. *Breast Cancer Res Treat*. 2016;157(1):167-178. doi:10.1007/s10549-016-3810-3
- 53. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN.
  Obesity and breast cancer survival in ethnically diverse postmenopausal women:
  The Multiethnic Cohort Study. *Breast Cancer Res Treat.* 2011;129(2):565-574.
  doi:10.1007/s10549-011-1468-4
- 54. Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable. *J Immunother Cancer*. 2019;7(1):1-11. doi:10.1186/s40425-019-0527-y
- 55. Crozier JA, Moreno-Aspitia A, Ballman K V., Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. *Cancer*. 2013;119(13):2447-2454. doi:10.1002/cncr.28051
- 56. Copson ER, Cutress RI, Maishman T, et al. Obesity and the outcome of young breast cancer patients in the UK: The POSH study. Ann Oncol. 2015;26(1):101-112. doi:10.1093/annonc/mdu509
- 57. Dahdaleh FS, Sherman SK, Poli EC, et al. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. *Surg* (*United States*). 2018;164(6):1223-1229. doi:10.1016/j.surg.2018.06.044
- 58. Dal Maso L, Zucchetto A, Talamini R, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. *Int J Cancer*. 2008;123(9):2188-

- 2194. doi:10.1002/ijc.23747
- 59. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. *J Pain Symptom Manage*. 2012;44(2):181-191. doi:10.1016/j.jpainsymman.2011.09.010
- 60. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM.
  Impact of body mass index on survival outcome among women with early stage
  triple-negative breast cancer. Clin Breast Cancer. 2012;12(5):364-372.
  doi:10.1016/j.clbc.2012.07.013
- Dickerman BA, Ahearn TU, Giovannucci E, et al. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. *Int J Cancer*. 2017;141(5):933-944. doi:10.1002/ijc.30803
- 62. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31. J Clin Oncol. 2009. doi:10.1200/JCO.2007.12.3752
- 63. Dignam JJ. Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer. *CancerSpectrum Knowl Environ*. 2003;95(19):1467-1476. doi:10.1093/jnci/djg060
- 64. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. *J Natl Cancer Inst*. 2006;98(22):1647-1654. doi:10.1093/jnci/djj442
- 65. Dignam JJ, Wieand K, Johnson KA, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. *Breast Cancer Res Treat*. 2006;97(3):245-254. doi:10.1007/s10549-005-9118-3

- 66. Doria-Rose VP, Newcomb PA, Morimoto LM, Hampton JM, Trentham-Dietz A. Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). *Cancer Causes Control.* 2006;17(1):63-70. doi:10.1007/s10552-005-0360-0
- 67. Drake I, Gullberg B, Sonestedt E, et al. Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. *Int J Cancer*. 2017;141(6):1170-1180. doi:10.1002/ijc.30824
- 68. Elwood JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, Campbell I. Obesity and breast cancer outcomes in chemotherapy patients in New Zealand a population-based cohort study. *BMC Cancer*. 2018;18(1):1-13. doi:10.1186/s12885-017-3971-4
- 69. Emaus A, Veierød MB, Tretli S, et al. Metabolic profile, physical activity, and mortality in breast cancer patients. *Breast Cancer Res Treat*. 2010;121(3):651-660. doi:10.1007/s10549-009-0603-y
- 70. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109(6):1192-1202. doi:10.1002/cncr.22534
- 71. Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM.
  Anthropometric measurements and survival after a prostate cancer diagnosis. Br J
  Cancer. 2018;118(4):607-610. doi:10.1038/bjc.2017.440
- 72. Fedirko V, Romieu I, Aleksandrova K, et al. Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. *Int J Cancer*. 2014;135(8):1949-1960. doi:10.1002/ijc.28841
- 73. Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of Systemic

- Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. *JAMA Oncol.* 2017;3(12):e172319. doi:10.1001/jamaoncol.2017.2319
- 74. Ferro M, Vartolomei MD, Russo GI, et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 2019;37(3):507-514. doi:10.1007/s00345-018-2397-1
- 75. Froehner M, Kellner AE, Koch R, Baretton GB, Hakenberg OW, Wirth MP. A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. *BMC Urol.* 2014;14(1):1-8. doi:10.1186/1471-2490-14-28
- 76. Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. *Obstet Gynecol.* 2014;124(6):1098-1104. doi:10.1097/AOG.0000000000000558
- 77. Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. *Ann Oncol.* 2015;26(11):2257-2266. doi:10.1093/annonc/mdv355
- 78. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. *Cancer*. 2007;109(6):1192-1202. doi:10.1002/cncr.22534
- 79. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. *J Clin Oncol.* 2012;30(2):164-171. doi:10.1200/JCO.2011.36.2723
- 80. Grossberg AJ, Chamchod S, Fuller CD, et al. Association of body composition with

- survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. *JAMA Oncol.* 2016;2(6):782-789. doi:10.1001/jamaoncol.2015.6339
- 81. Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013. doi:10.1002/cncr.27938
- 82. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. *Cancer*. 2007;110(7):1478-1484. doi:10.1002/cncr.22932
- 83. McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death. Clin Gastroenterol Hepatol. 2017. doi:10.1016/j.cgh.2016.10.012
- 84. Han M, Trock BJ, Partin AW, et al. The impact of preoperative erectile dysfunction on survival after radical prostatectomy. *BJU Int*. 2010;106(11):1612-1617. doi:10.1111/j.1464-410X.2010.09472.x
- 85. Han X, Stevens J, Truesdale KP, et al. Body mass index at early adulthood, subsequent weight change and cancer incidence and mortality. *Int J Cancer*. 2014;135(12):2900-2909. doi:10.1002/ijc.28930
- 86. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SCJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. *Ann Oncol.* 2012;23(7):1771-1780. doi:10.1093/annonc/mdr534
- 87. Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: Results from a prospective

- cohort study. *Eur J Cancer Prev.* 2010;19(5):366-373. doi:10.1097/CEJ.0b013e32833b4828
- 88. His M, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L. Prediagnostic body size and breast cancer survival in the E3N cohort study. *Int J Cancer*. 2016;139(5):1053-1064. doi:10.1002/ijc.30158
- 89. Ho T, Gerber L, Aronson WJ, et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: Biology or Technique? Results from the SEARCH database. *Eur Urol.* 2012;62(5):910-916. doi:10.1016/j.eururo.2012.08.015
- 90. Houdek MT, Griffin AM, Ferguson PC, Wunder JS. Morbid Obesity Increases the Risk of Postoperative Wound Complications, Infection, and Repeat Surgical Procedures Following Upper Extremity Limb Salvage Surgery for Soft Tissue Sarcoma. *Hand*. 2019;14(1):114-120. doi:10.1177/1558944718797336
- 91. Hu Qinchao, Peng J, Chen X, et al. Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. Oral Oncol. 2019;89(December 2018):14-22. doi:10.1016/j.oraloncology.2018.12.006
- Rosenberg L, Czene K, Hall P. Obesity and poor breast cancer prognosis: An illusion because of hormone replacement therapy. Br J Cancer. 2009;100(9):1486-1491. doi:10.1038/sj.bjc.6605025
- 93. Ruterbusch JJ, Ali-Fehmi R, Olson SH, et al. The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am J Obstet Gynecol. 2014. doi:10.1016/j.ajog.2014.06.036
- 94. Iyengar NM, Kochhar A, Morris PG, et al. NIH Public Access. 2015;120(7):983-991. doi:10.1002/cncr.28532.lmpact

- 95. Izumida T, Nakamura Y, Ishikawa S. Impact of body mass index and metabolically unhealthy status on mortality in the Japanese general population: The JMS cohort study. *PLoS One*. 2019;14(11):1-16. doi:10.1371/journal.pone.0224802
- 96. Janssen SJ, van der Heijden AS, van Dijke M, et al. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? Clin Orthop Relat Res. 2015;473(10):3112-3121. doi:10.1007/s11999-015-4446-z
- 97. Jayasekara H, English DR, Haydon A, et al. Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. *Int J Cancer*. 2018;142(2):238-250. doi:10.1002/ijc.31049
- 98. Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and Cancer Subgroups in the UK Biobank, and their modification by smoking. *Diabetes Care*. 2018;41(9):1878-1886. doi:10.2337/dc17-2508
- 99. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. *BMC Cancer*. 2015;15(1). doi:10.1186/s12885-015-1879-4
- 100. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. *Ann Oncol.* 2013;24(10):2506-2514. doi:10.1093/annonc/mdt224
- 101. Kaidar-Person O, Badarna H, Bar-Sela G. Bevacizumab for metastatic colon cancer: Does patient BMI influence survival? *Anticancer Drugs*. 2015;26(3):363-366.

- doi:10.1097/CAD.00000000000000201
- 102. Kalb M, Langheinrich MC, Merkel S, et al. Influence of body mass index on long-term outcome in patients with rectal cancer-a single centre experience. Cancers (Basel). 2019;11(5). doi:10.3390/cancers11050609
- 103. Katzmarzyk PT, Reeder BA, Elliott S, et al. Body mass index and risk of cardiovascular disease, cancer and all-cause mortality. Can J Public Heal. 2012;103(2):147-151. doi:10.1007/bf03404221
- 104. Kawai M, Tomotaki A, Miyata H, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. Cancer Med. 2016;5(6):1328-1340. doi:10.1002/cam4.678
- 105. Keegan THM, Milne RL, Andrulis IL, et al. Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: Results from the breast cancer family registry. *Breast Cancer Res Treat*. 2010;123(2):531-542. doi:10.1007/s10549-010-0774-6
- 106. Keizman D, Gottfried M, Ish-Shalom M, et al. Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. *Oncologist*. 2014;19(1):51-60. doi:10.1634/theoncologist.2012-0335
- 107. Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB. Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO cancer screening trial. *J Natl Cancer Inst.* 2017;109(3):1-9. doi:10.1093/jnci/djw225
- 108. Kenfield SA, Batista JL, Jahn JL, et al. Development and Application of a Lifestyle

- Score for Prevention of Lethal Prostate Cancer. *J Natl Cancer Inst.* 2016;108(3). doi:10.1093/jnci/djv329
- 109. Khan S, Cai J, Nielsen ME, et al. The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC. *Prostate*. 2017;77(8):878-887. doi:10.1002/pros.23342
- 110. Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. *JAMA Oncol.* 2019. doi:10.1001/jamaoncol.2019.5241
- 111. Kitahara CM, Flint AJ, Berrington de Gonzalez A, et al. Association between Class III Obesity (BMI of 40-59 kg/m2) and Mortality: A Pooled Analysis of 20 Prospective Studies. *PLoS Med.* 2014;11(7). doi:10.1371/journal.pmed.1001673
- 112. Minlikeeva AN, Cannioto R, Jensen A, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019. doi:10.1007/s10552-019-01157-3
- 113. Kotsopoulos J, Moody JRK, Fan I, et al. Height, weight, BMI and ovarian cancer survival. *Gynecol Oncol.* 2012;127(1):83-87. doi:10.1016/j.ygyno.2012.05.038
- 114. Kristensen AB, Hare-Bruun H, Høgdall CK, Rudnicki M. Influence of Body Mass Index on Tumor Pathology and Survival in Uterine Cancer: A Danish Register Study. Int J Gynecol Cancer. 2017;27(2):281-288. doi:10.1097/IGC.0000000000000874
- 115. Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast cancer in the after Breast Cancer Pooling Project. *Breast Cancer Res Treat*. 2012;132(2):729-739. doi:10.1007/s10549-011-1914-3

- 116. Kwan ML, John EM, Caan BJ, et al. Obesity and mortality after breast cancer by Race/Ethnicity: The california breast cancer survivorship consortium. *Am J Epidemiol.* 2014;179(1):95-111. doi:10.1093/aje/kwt233
- 117. Ladoire S, Dalban C, Roché H, et al. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. *Eur J Cancer*. 2014;50(3):506-516. doi:10.1016/j.ejca.2013.11.013
- 118. Larsen SB, Kroman N, Ibfelt EH, Christensen J, Tjønneland A, Dalton SO. Influence of metabolic indicators, smoking, alcohol and socioeconomic position on mortality after breast cancer. *Acta Oncol (Madr)*. 2015;54(5):780-788.
  doi:10.3109/0284186X.2014.998774
- 119. Siegel EM, Nabors LB, Thompson RC, et al. Prediagnostic body weight and survival in high grade glioma. J Neurooncol. 2013. doi:10.1007/s11060-013-1150-2
- 120. Lee WK, Byun SS, Kim HH, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: A multicenter study. *Int J Urol*. 2010;17(11):898-904. doi:10.1111/j.1442-2042.2010.02630.x
- 121. Gama RR, Song Y, Zhang Q, et al. Body mass index and prognosis in patients with head and neck cancer. Head Neck. 2017. doi:10.1002/hed.24760
- 122. Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. *Int J Epidemiol*. 2011;40(1):174-182. doi:10.1093/ije/dyq134
- 123. Li D, Morris JS, Day RS, Bondy ML, Abbruzzese JL. Body Mass Index and Risk, Age of Onset ,. *JAMA*. 2014;301(24):2553-2562.
- 124. Liss M, Natarajan L, Hasan A, Noguchi JL, White M, Parsons JK. Physical Activity

- Decreases Kidney Cancer Mortality. *Curr Urol.* 2017;10(4):193-198. doi:10.1159/000447180
- 125. Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2005;14(7):1686-1691. doi:10.1158/1055-9965.EPI-05-0042
- 126. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol.* 2008;9(11):1039-1047. doi:10.1016/S1470-2045(08)70235-3
- 127. Maj-Hes AB, Mathieu R, Özsoy M, et al. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urol Oncol Semin Orig Investig*. 2017;35(7):460.e1-460.e8. doi:10.1016/j.urolonc.2017.01.022
- 128. Martini DJ, Kline MR, Liu Y, et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.

  Cancer. 2020;126(3):575-582. doi:10.1002/cncr.32576
- 129. Maskarinec G, Pagano I, Lurie G, Bantum E, Gotay CC, Issell BF. Factors affecting survival among women with breast cancer in Hawaii. *J Women's Heal*. 2011;20(2):231-237. doi:10.1089/jwh.2010.2114
- 130. Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH. Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. *J Gastrointest Surg.* 2010;14(5):849-857. doi:10.1007/s11605-010-1163-5
- 131. Matsuo K, Moeini A, Cahoon SS, et al. Weight Change Pattern and Survival

- Outcome of Women with Endometrial Cancer. *Ann Surg Oncol.* 2016;23(9):2988-2997. doi:10.1245/s10434-016-5237-9
- 132. Song X, Pitkäniemi J, Gao W, et al. Relationship between body mass index and mortality among Europeans. Eur J Clin Nutr. 2012;66(2):156-165.
  doi:10.1038/ejcn.2011.145
- 133. Mazzarella L, Disalvatore D, Bagnardi V, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer*. 2013;49(17):3588-3597. doi:10.1016/j.ejca.2013.07.016
- 134. McCullough LE, Chen J, Cho YH, et al. DNA methylation modifies the association between obesity and survival after breast cancer diagnosis. *Breast Cancer Res*Treat. 2016;156(1):183-194. doi:10.1007/s10549-016-3724-0
- 135. McCullough ML, Feigelson HS, Diver WR, Patel A V., Thun MJ, Calle EE. Risk factors for fatal breast cancer in African-American women and white women in a large US prospective cohort. Am J Epidemiol. 2005;162(8):734-742. doi:10.1093/aje/kwi278
- 136. Mcquade JL, Daniel CR, Hess PKR, et al. HHS Public Access. 2018;19(3):310-322. doi:10.1016/S1470-2045(18)30078-0.The
- 137. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012.
  doi:10.1097/SLA.0b013e3182456aa2
- 138. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast

- cancer. J Clin Oncol. 2011;29(19):2645-2652. doi:10.1200/JCO.2010.33.4441
- 139. Meyer J, Rohrmann S, Bopp M, et al. Impact of smoking and excess body weight on overall and site-specific cancer mortality risk. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1516-1522. doi:10.1158/1055-9965.EPI-15-0415
- 140. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. *Cancer*. 2003;98(3):484-495. doi:10.1002/cncr.11544
- 141. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803. *J Clin Oncol*. 2008;26(25):4109-4115. doi:10.1200/JCO.2007.15.6687
- 142. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114. *J Clin Oncol*. 2004;22(4):648-657. doi:10.1200/JCO.2004.07.121
- 143. Møller H, Roswall N, Hemelrijck M Van, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark. *Int J Cancer*. 2015;136(8):1940-1947. doi:10.1002/ijc.29238
- 144. Montgomery RB, Goldman B, Tangen CM, et al. Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916. *J Urol.* 2007;178(5):1946-1951. doi:10.1016/j.juro.2007.07.026
- 145. Morikawa T, Kuchiba A, Liao X, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. *Int J Cancer*. 2012;131(5):1169-1178.

- doi:10.1002/ijc.26495
- 146. Tseng CH. Obesity paradox: Differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226(1):186-192. doi:10.1016/j.atherosclerosis.2012.09.004
- 147. Xie HJ, Zhang X, Wei ZQ, Long H, Rong TH, Su XD. Effect of body mass index on survival of patients with stage I non-small cell lung cancer. Chin J Cancer. 2017;36(1):1-10. doi:10.1186/s40880-016-0170-7
- 148. Nagle CM, Crosbie EJ, Brand A, et al. The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. *Gynecol Oncol.* 2018;150(1):99-105. doi:10.1016/j.ygyno.2018.04.006
- 149. Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. *Interact Cardiovasc Thorac Surg*. 2016;23(4):560-566. doi:10.1093/icvts/ivw175
- 150. Nechuta SJ, Shu XO, Li HL, et al. Combined impact of lifestyle-related factors on total and cause-specific mortality among chinese women: Prospective cohort study. PLoS Med. 2010;7(9). doi:10.1371/journal.pmed.1000339
- 151. Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. *Am J Clin Oncol Cancer Clin Trials*. 2014;37(2):131-134. doi:10.1097/COC.0b013e318277d5f4
- 152. Nichols HB, Trentham-dietz A, Egan KM, et al. Disease Mortality. 2010;18(5):1403-1409. doi:10.1158/1055-9965.EPI-08-1094.Body

- 153. Nonemaker JM, Garrett-Mayer E, Carpenter MJ, et al. The Risk of Dying from Lung Cancer by Race: A Prospective Cohort Study in a Biracial Cohort in Charleston, South Carolina. *Ann Epidemiol*. 2009;19(5):304-310. doi:10.1016/j.annepidem.2008.12.017
- 154. Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: Findings from the Swedish women's lifestyle and health cohort. *BMC Cancer*. 2019;19(1):1-9. doi:10.1186/s12885-019-5985-6
- 155. Ogino S, Nosho K, Baba Y, et al. A Cohort study of STMN1 expression in colorectal cancer: Body mass index and prognosis. *Am J Gastroenterol.* 2009;104(8):2047-2056. doi:10.1038/ajg.2009.281
- 156. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. *Breast Cancer Res.* 2011;13(2):R34. doi:10.1186/bcr2856
- 157. Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. *Int J Cancer*. 2010;127(10):2412-2419.

  doi:10.1002/ijc.25240
- 158. Oudanonh T, Nabi H, Ennour-Idrissi K, Lemieux J, Diorio C. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. *Int J Cancer*. 2019;00. doi:10.1002/ijc.32621
- 159. Pajares B, Pollán M, Martín M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis. *Breast Cancer Res.* 2013;15(6):1-14.

doi:10.1186/bcr3572

- 160. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. *Urology*. 2006;68(4):741-746. doi:10.1016/j.urology.2006.05.024
- 161. Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants.

  Lancet Oncol. 2010;11(8):741-752. doi:10.1016/S1470-2045(10)70141-8
- 162. Patel GS, Ullah S, Beeke C, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. *Cancer Med.* 2015;4(10):1461-1471. doi:10.1002/cam4.490
- 163. Pelser C, Arem H, Pfeiffer RM, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. Cancer. 2014;120(10):1540-1547. doi:10.1002/cncr.28573
- 164. Pfeiler G, Stöger H, Dubsky P, et al. Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptorpositive breast cancer: An analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013;108(7):1408-1414. doi:10.1038/bjc.2013.114
- 165. Yu M-L, Asal NR, Geyer JR. Later recurrence and longer survival among obese patients with renal cell carcinoma. Cancer. 1991. doi:10.1002/1097-0142(19911001)68:73.0.CO;2-5
- 166. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. *J Clin Oncol*. 2007;25(17):2345-2351. doi:10.1200/JCO.2006.08.6819

- 167. Potharaju M, Mangaleswaran B, Mathavan A, et al. Body Mass Index as a Prognostic Marker in Glioblastoma Multiforme: A Clinical Outcome. *Int J Radiat Oncol Biol Phys.* 2018;102(1):204-209. doi:10.1016/j.ijrobp.2018.05.024
- 168. Previs RA, Kilgore J, Craven R, et al. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. *Int J Gynecol Cancer*. 2014;24(4):670-675. doi:10.1097/IGC.000000000000000000
- 169. Prizment AE, Flood A, Anderson KE, Folsom AR. anthropometric characteristics: the lowa Women's Health Study. *Cancer Epidemiol Biomarkers Prev*. 2010;19(9):2229-2237. doi:10.1158/1055-9965.EPI-10-0522.Survival
- 170. Probst-Hensch NM, Steiner JHB, Schraml P, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity. 

  Clin Cancer Res. 2010;16(3):1025-1032. doi:10.1158/1078-0432.CCR-09-0957
- 171. Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. *J Urol.* 2016;195(2):270-276. doi:10.1016/j.juro.2015.08.072
- 172. Qi Y, Schild SE, Mandrekar SJ, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. *J Thorac Oncol.* 2009;4(9):1075-1082. doi:10.1097/JTO.0b013e3181ae27f5
- 173. Roque DR, Taylor KN, Palisoul M, et al. Gemcitabine and Docetaxel Compared with Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma. *Int J Gynecol Cancer*. 2016;26(3):505-511. doi:10.1097/IGC.000000000000000034

- 174. Rudman SM, Gray KP, Batista JL, et al. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. *BJU Int.* 2016;118(6):919-926. doi:10.1111/bju.13428
- 175. Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. *Lancet Oncol.* 2020;21(2):283-293. doi:10.1016/S1470-2045(19)30797-1
- 176. Sasazuki S, Inoue M, Tsuji I, et al. Body mass index and mortality from all causes and major causes in Japanese: Results of a Pooled analysis of 7 large-scale cohort studies. *J Epidemiol.* 2011;21(6):417-430. doi:10.2188/jea.JE20100180
- 177. Schiffmann J, Salomon G, Tilki D, et al. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. *Urol Oncol Semin Orig Investig*. 2017;35(5):243-249. doi:10.1016/j.urolonc.2016.12.014
- 178. Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis.
  Cancer Causes Control. 2014;25(10):1407-1418. doi:10.1007/s10552-014-0435-x
- 179. Seidelin UH, Ibfelt E, Andersen I, et al. Does stage of cancer, comorbidity or lifestyle factors explain educational differences in survival after endometrial cancer? A cohort study among Danish women diagnosed 2005–2009. *Acta Oncol (Madr)*. 2016;55(6):680-685. doi:10.3109/0284186X.2015.1136750
- 180. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease- free survival. *Ann Intern Med*. 1992;116(1):26-32. doi:10.7326/0003-4819-116-1-26
- 181. Shah MS, Fogelman DR, Raghav KPS, et al. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. *Cancer*.

- 2015;121(17):2968-2975. doi:10.1002/cncr.29440
- 182. Shelke, A. R., Roscoe, J. A., Morrow, G. R., Colman, L. K., Banerjee, T. K., & Kirshner JJ. 基因的改变NIH Public Access. *Bone*. 2008;23(1):1-7. doi:10.1038/jid.2014.371
- 183. Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. *J Thorac Oncol*. 2019. doi:10.1016/j.jtho.2019.05.031
- 184. Silventoinen K, Tynelius P, Rasmussen F. Weight status in young adulthood and survival after cardiovascular diseases and cancer. *Int J Epidemiol*. 2014;43(4):1197-1204. doi:10.1093/ije/dyu091
- 185. Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. *J Clin Oncol*. 2012;30(4):406-412. doi:10.1200/JCO.2011.39.2563
- 186. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of Obesity With Tumor Characteristics and Treatment Failure of Prostate Cancer in African-American and European American Men. *J Urol.* 2007;178(5):1939-1945. doi:10.1016/j.juro.2007.07.021
- 187. Sparano JA, Wang M, Zhao F, et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *J Natl Cancer Inst*. 2012;104(5):406-414. doi:10.1093/jnci/djr543
- 188. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior

- outcomes in hormone receptor-positive operable breast cancer. *Cancer*. 2012;118(23):5937-5946. doi:10.1002/cncr.27527
- 189. Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. *BJU Int.* 2012;110(11 B). doi:10.1111/j.1464-410X.2012.11155.x
- Spreafico A, Coate L, Zhai R, et al. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. *Cancer Epidemiol*. 2017;47:28-34. doi:10.1016/j.canep.2016.11.009
- 191. Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. *J Women's Heal*. 2013;22(12):1043-1048.

  doi:10.1089/jwh.2013.4375
- 192. Sun L, Zhu Y, Qian Q, Tang L. Body mass index and prognosis of breast cancer.

  Med (United States). 2018;97(26). doi:10.1097/MD.000000000011220
- 193. Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA. Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. *Cancer Causes Control*. 2015;26(12):1803-1811.
  doi:10.1007/s10552-015-0673-6
- 194. Sundelöf M, Lagergren J, Ye W. Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. *Eur J Cancer*. 2008;44(11):1566-1571. doi:10.1016/j.ejca.2008.04.002
- 195. Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, De Vries EGE, Vonk JM.

- BMI and lifetime changes in BMI and cancer mortality risk. *PLoS One*. 2015;10(4):1-16. doi:10.1371/journal.pone.0125261
- 196. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. *Breast Cancer Res Treat*.
  2014;146(1):189-197. doi:10.1007/s10549-014-3002-y
- 197. Thrift AP, Nagle CM, Fahey PP, Smithers BM, Watson DI, Whiteman DC. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. *Cancer Causes Control.* 2012;23(4):555-564. doi:10.1007/s10552-012-9913-1
- 198. Todo Y, Okamoto K, Minobe S, Kato H. Clinical significance of surgical staging for obese women with endometrial cancer: a retrospective analysis in a Japanese cohort. *Jpn J Clin Oncol.* 2014;44(10):903-909. doi:10.1093/jjco/hyu106
- 199. Trial EI, Sorbye H, Mauer M, et al. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients.
  2012;255(3). doi:10.1097/SLA.0b013e3182456aa2
- 200. Trivers KF, De Roos AJ, Gammon MD, et al. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. *Clin Gastroenterol Hepatol*. 2005;3(3):225-230. doi:10.1016/S1542-3565(04)00613-5
- 201. Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: A large single-institution study. *J Gastrointest Surg.* 2010;14(7):1143-1150. doi:10.1007/s11605-010-1201-3
- 202. Tseng CH. Factors associated with cancer- and non-cancer-related deaths among Taiwanese patients with diabetes after 17 years of follow-up. *PLoS One*.

- 2016;11(12):1-16. doi:10.1371/journal.pone.0147916
- 203. Turner MC, Krewski D, Pope CA, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Respir Crit Care Med*. 2011;184(12):1374-1381. doi:10.1164/rccm.201106-1011OC
- 204. Tyler CP, Whiteman MK, Zapata LB, et al. The effect of body mass index and weight change on epithelial ovarian cancer survival in younger women: A long-term follow-up study. *J Women's Heal*. 2012;21(8):865-871. doi:10.1089/jwh.2012.3487
- 205. Valentijn TM, Galal W, Hoeks SE, Van Gestel YR, Verhagen HJ, Stolker RJ. Impact of obesity on postoperative and long-term outcomes in a general surgery population: A retrospective cohort study. World J Surg. 2013;37(11):2561-2568.
  doi:10.1007/s00268-013-2162-y
- 206. Vidal AC, Howard LE, Sun SX, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *Prostate Cancer Prostatic Dis.* 2017;20(1):72-78. doi:10.1038/pcan.2016.47
- 207. Vidal AC, Howard LE, de Hoedt A, et al. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *BJU Int*. 2018;122(1):76-82. doi:10.1111/bju.14193
- 208. Wang N, Khankari NK, Cai H, et al. Prediagnosis body mass index and waist–hip circumference ratio in association with colorectal cancer survival. *Int J Cancer*. 2017;140(2):292-301. doi:10.1002/ijc.30459
- 209. Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function

- during tumor progression and PD-1 checkpoint blockade. *Nat Med.* 2019;25(1):141-151. doi:10.1038/s41591-018-0221-5
- 210. Warren LEG, Ligibel JA, Chen YH, Truong L, Catalano PJ, Bellon JR. Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. *Ann Surg Oncol.* 2016;23(12):3870-3879. doi:10.1245/s10434-016-5437-3
- 211. Widschwendter P, Friedl TWP, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial. *Breast Cancer Res.* 2015;17(1):1-11. doi:10.1186/s13058-015-0639-3
- 212. Wu W, Liu X, Chaftari P, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: A retrospective review. *PLoS One*. 2015;10(3):1-17. doi:10.1371/journal.pone.0122047
- 213. Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. *Tumor Biol.* 2014;35(3):2035-2045. doi:10.1007/s13277-013-1270-5
- 214. Xu H, Cupples LA, Stokes A, Liu CT. Association of Obesity With Mortality Over 24

  Years of Weight History: Findings From the Framingham Heart Study. *JAMA Netw*open. 2018;1(7):e184587. doi:10.1001/jamanetworkopen.2018.4587
- 215. Xu H, Tan P, Zheng X, et al. Metabolic syndrome and upper tract urothelial carcinoma: A retrospective analysis from a large Chinese cohort. *Urol Oncol Semin Orig Investig.* 2019;37(4):291.e19-291.e28. doi:10.1016/j.urolonc.2018.12.005
- 216. Yang L, Klint Å, Lambe M, et al. Predictors of ovarian cancer survival: A population-based prospective study in Sweden. *Int J Cancer*. 2008;123(3):672-679.
  doi:10.1002/ijc.23429

- 217. Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. *Br J Surg*. 2019;106(9):1228-1236. doi:10.1002/bjs.11231
- 218. Yano Y, Kario K, Ishikawa S, et al. Associations between diabetes, leanness, and the risk of death in the japanese general population: The Jichi medical school cohort study. *Diabetes Care*. 2013;36(5):1186-1192. doi:10.2337/dc12-1736
- 219. Yoon HH, Lewis MA, Shi Q, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. *J Clin Oncol*. 2011;29(34):4561-4567. doi:10.1200/JCO.2011.37.1260
- 220. Yoon LS, Goodman MT, Rimel BJ, Jeon CY. Statin use and survival in elderly patients with endometrial cancer. *Gynecol Oncol.* 2015;137(2):252-257. doi:10.1016/j.ygyno.2015.01.549
- 222. Yuan C, Bao Y, Wu C, et al. Prediagnostic body mass index and pancreatic cancer survival. *J Clin Oncol.* 2013. doi:10.1200/JCO.2013.51.7532
- 223. Zheng J, Li Y, Zhu S, et al. NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. *Oncotarget*. 2016;7(2):1311-1322.
  doi:10.18632/oncotarget.6182
- 224. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst.* 2003. doi:10.1093/jnci/djg022

- 225. Campbell KL, Foster-Schubert KE, Alfano CM, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: Randomized controlled trial. *J Clin Oncol.* 2012. doi:10.1200/JCO.2011.37.9792
- 226. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel A V., Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The cancer prevention study-II nutrition cohort. *J Clin Oncol*. 2012. doi:10.1200/JCO.2011.38.0287
- 227. Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. *Arch Physiol Biochem*. 2008. doi:10.1080/13813450801954303
- 228. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). *JAMA J Am Med Assoc.* 2009. doi:10.1001/jama.2008.864
- 229. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol. 2012. doi:10.1093/annonc/mdr603
- 230. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia:
  Understanding the molecular basis. *Nat Rev Cancer*. 2014. doi:10.1038/nrc3829
- 231. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. *Br J Cancer*. 2002. doi:10.1038/sj.bjc.6600466
- 232. Patel JD, Pereira JR, Chen J, et al. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung

- cancer patients. Ann Oncol. 2016. doi:10.1093/annonc/mdw211
- 233. Naik GS, Waikar SS, Johnson AEW, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: Exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. *J Immunother Cancer*. 2019. doi:10.1186/s40425-019-0512-5
- 234. Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. *PLoS One*. 2018. doi:10.1371/journal.pone.0204729
- 235. Santoni M, Cortellini A, Buti S. Unlocking the secret of the obesity paradox in renal tumours. *Lancet Oncol.* 2020. doi:10.1016/S1470-2045(19)30783-1
- 236. Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. *Lancet Oncol.* 2020. doi:10.1016/S1470-2045(19)30797-1
- 237. Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective Memory Responses to Infection. *Immunity*. 2017. doi:10.1016/j.immuni.2017.11.009
- 238. Tucker JM, Tucker LA, Lecheminant J, Bailey B. Obesity increases risk of declining physical activity over time in women: A prospective cohort study. *Obesity*. 2013. doi:10.1002/oby.20415
- 239. Pietiläinen KH, Kaprio J, Borg P, et al. Physical inactivity and obesity: A vicious circle. *Obesity*. 2008. doi:10.1038/oby.2007.72
- 240. Spei ME, Samoli E, Bravi F, La Vecchia C, Bamia C, Benetou V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and

- breast cancer survival. Breast. 2019. doi:10.1016/j.breast.2019.02.001
- 241. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: A meta-Analysis of prospective cohort studies. *Int J Cancer*. 2013. doi:10.1002/ijc.28208
- 242. MacMahon S, Baigent C, Duffy S, et al. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. *Lancet*. 2009. doi:10.1016/S0140-6736(09)60318-4
- 243. Renehan AG, Harvie M, Cutress RI, et al. How to manage the obese patient with cancer. *J Clin Oncol.* 2016. doi:10.1200/JCO.2016.69.1899
- 244. Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. *Ann Oncol.* 2013. doi:10.1093/annonc/mdt294

Author, Year	N° pts	N° of obese (%)	Study type	Country	Disease	Median Follow Up (months)	Disease stage	Treatment	Type of analysis	os	css	DFS/PFS	Quality (NOS- METRICS)
Abdel- Rahman/2019 <sup>21</sup>	145544	18131 (23.7)	Population-based randomized	US	Lung	135	Early + advanced	-	MVA	1	-	-	12
Abdullah/2011 <sup>22</sup>	5036	567 (11)	Retrospective (cohort)	Various	Various	-	-	-	MVA	-	1	-	5
Abrahamson/2006 <sup>23</sup>	1254	-	Retrospective	US	Breast	-	Early + advanced	-	MVA	1	-	-	5
Abukabar/2018 <sup>24</sup>	3012	433 (13)	Retrospective	Malaysia	Breast	24	Early + advanced	S ± RT ± CT	MVA	1	-	1	6
Ademuyiawa/2011 <sup>25</sup>	418	164 (39.2)	Retrospective	US	Breast	37.2	Early	S	MVA	1	-	1	6
Akinyemiju/2018 <sup>26</sup>	22514	8786 (39)	Prospective	US	Various	78	-	-	MVA	-	1	-	8
Aldrich/2013 <sup>28</sup>	501	126 (25.1)	Prospective (cohort)	US	NSCLC	16	Early + advanced	-	MVA	1	-	-	7
Alsaker/2011 <sup>29</sup>	2640	432 (16.3)	Retrospective	Norway	Breast	69	Early + advanced	-	MVA	-	1	-	7
Arce-Salinas/2014 <sup>30</sup>	819	596 (74)	Retrospective	Mexico	Breast	28	Advanced	CT	UVA	/	-	✓	6
Arem/2013 <sup>31</sup>	1400	610 (43)	Retrospective	US	Uterus	61.2	Early + advanced	-	MVA	1	1	-	7
Ata/2018 <sup>32</sup>	8352	2841 (34)	Retrospective	US	HCC	60	-	Liver transplantation	MVA	1	1	-	7
Bandera/2015 <sup>33</sup>	1846	547 (29.6)	Cohort study	US	Ovarian	-	Early + advanced	СТ	MVA	1	1	-	5
Bassett/2012 <sup>35</sup>	16525	247 (18)	Prospective (cohort)	Australia	Prostate	180	-	-	MVA	-	1	-	12
Beasley/2012 <sup>27</sup>	13302	2330 (17.5)	Metanalysis	US, China	Breast	-	Early	All	MVA	1	1	1	-
Blair/2019 <sup>36</sup>	859	195 (22.7)	Cohort study	US	Breast	94	Early + advanced	CT, RT, HT	MVA	-	1	-	8
Boggs/2011 <sup>37</sup>	51695	23656 (46)	Prospective	US	Various	-	-	-	MVA	-	1	-	8
Bonn/2014 <sup>38</sup>	4376	483 (11)	Retrospective	Sweden	Prostate	48	Early	S, RT	MVA	1	1	1	6
Boyle/2013 <sup>39</sup>	879	258 (29.4)	Retrospective	Australia	CRC	67.2	Early	-	MVA	1	1	1	7
Braithwaite/2010 <sup>40</sup>	2202	500 (22.7)	Retrospective	US	Breast	88	Early	-	MVA	1	1	-	8
Campbell/2015 <sup>44</sup>	5615	1483 (26.4)	Prospective	Various	CRC	-	Early + advanced	S, CT	MVA	1	1	-	5
Caan/2008 <sup>43</sup>	1692	409 (24.2)	Retrospective	US	Breast	-	Early	S / adjuvant	MVA	1	1	/	5
Carr/2018 <sup>45</sup>	521	-	Retrospective	Italy	HCC	-	Early + advanced	-	MVA	1	-	-	5
Cecchini/2016 <sup>46</sup>	5265	1794 (34)	Phase III (NSABP-B30)	US	Breast	108	Early	СТ	MVA	1	-	-	-
Cecchini/2016 <sup>46</sup>	2102	664 (31.6)	Phase III (NSABP-B31)	US	Breast	99.6	Early	CT + TTZ	MVA	1	-	-	-
Cecchini/2016 <sup>46</sup>	3311	1186 (35.8)	Phase III (NSABP-B34)	US	Breast	100.8	Early	BPS vs Placebo*	MVA	1	-	-	-
Cecchini/2016 <sup>46</sup>	4860	1917 (39.4)	Phase III (NSABP-B38)	US	Breast	70.8	Early	СТ	MVA	1	-	-	-
Cespedes Feliciano/2017 <sup>47</sup>	2470	-	Retrospective	US	CRC	72	Early	-	MVA	1	1	-	7
Chang/2000 <sup>48</sup>	177	64 (36.2)	Retrospective	US	Breast	100	Advanced	Induction CT / S	MVA	1	-	-	8

Chen/2010 <sup>49</sup>	5042	283 (5.6)	Retrospective	China	Breast	6.5	Early + advanced	S, CT, RT, HT	MVA	1	1	-	6
Hung/2018 <sup>34</sup>	33551	2362 (7.1)	Retrospective (cohort)	Taiwan	Solid cancers	43.8	Early + advanced	S	MVA	1	1	-	6
Chromecki/2012 <sup>50</sup>	4118	1739 (42.2)	Retrospective	Various	Bladder	44	Early	S ± adjuvant CT	MVA	1	1	1	7
Chung/2017 <sup>51</sup>	8742	75 (8.5)	Retrospective	South Korea	Breast	92	Early	All	MVA	/	1	-	9
Clark/2013 <sup>41</sup>	99	40 (41)	Retrospective	US	CRC	39.4	Early	CT + RT	MVA	/	-	1	6
Cleveland/2012 <sup>42</sup>	1447	319 (22)	Prospective (case-control)	US	Breast	-	-	-	MVA	1	1	-	8
Connor/2016 <sup>52</sup>	2478	142 (5.7)	Prospective (registry)	US	Breast	129.6	Early + advanced	-	MVA	1	1	-	12
Conroy/2011 <sup>53</sup>	3842	901 (23)	Prospective (cohort)	US	Breast	74.4	Early + advanced	S ± CT/HT and/or RT	MVA	✓	1	-	11
Copson/2014 <sup>56</sup>	2843	533 (18.7)	Prospective	UK	Breast	70.4	Early + advanced	S, RT, CT, HT	MVA	1	-	1	11
Cortellini/2019 <sup>54</sup>	976	377 (38.6)	Retrospective	Italy	Various	17.2	Advanced	Anti-PD-1/PD-L1	MVA	1	-	1	6
Crozier 2013 <sup>55</sup>	3017	1298 (43)	Retrospective	US	Breast	63.6	Early	-	MVA	-	1	/	8
Dahdaleh/2018 <sup>57</sup>	1543	529 (34.3)	Retrospective (cohort)	US	CRC	30.9	Early	S, adjuvant CT	MVA	1	-	1	6
Dalal/2012 <sup>59</sup>	41	8 (20)	Prospective	US	Pancreas	-	Advanced	CTRT	MVA	1	-	-	7
Dal Maso/2008 <sup>58</sup>	1453	172 (11.8)	Retrospective	Italy	Breast	-	Early	S / adjuvant	UVA	1	1	-	5
Dawood/2012 <sup>60</sup>	2311	825 (35.7)	Retrospective	US	Breast (TN)	39	Early	S	MVA	1	-	1	6
Dickerman/2017 <sup>61</sup>	5158	564 (10.9)	Retrospective	US	Prostate	-	Early	All	MVA	-	1	-	5
Dignam/2003 <sup>63</sup>	3385	395 (11.67)	Retrospective	US	Breast	-	Early	S + HT	MVA	1	1	1	5
Dignam/2006 <sup>64</sup>	4077	1056 (25.9)	Retrospective	US	Breast	-	-	-	MVA	1	1	1	5
Dignam/2006 <sup>65</sup>	4288	812 (9.5)	Retrospective	North America	CRC	-	Early	CT	MVA	1	1	1	5
Doria-Rose/2006 <sup>66</sup>	633	96 (15.2)	Retrospective	US	CRC (women)	112.8	Early	S / others	MVA	1	1	-	8
Drake/2017 <sup>67</sup>	7061	3220 (45.6)	Prospective (cohort)	Sweden	Various	202	Early + advanced	All	MVA	1	1	-	12
Efstathiou/2008 <sup>62</sup>	945	145 (15.3)	Prospective	US	Prostate	97.2	Advanced	RT +/- Goserelin	MVA	1	1	-	11
Emaus/2009 <sup>69</sup>	1364	147 (10.78)	Retrospective	Norway	Breast	98.4	Early + advanced	-	MVA	1	1	-	8
Farris/2018 <sup>71</sup>	987	192 (19.4)	Prospective (cohort)	Canada	Prostate	228	Early + advanced	S, RT, HT	MVA	1	1	-	12
Fedirko/2014 <sup>72</sup>	3924	689 (17.5)	Prospective	Western Europe	Colorectal	49	Early + advanced	-	MVA	1	1	-	7
Feliciano/2017 <sup>73</sup>	1559	471 (30.2)	Retrospective	US	Breast	108	Early	All	MVA	-	1	1	8
Ferro/2018 <sup>74</sup>	1155	224 (21.4)	Retrospective	Italy	Bladder	48	Early	TURBT + BCG	MVA	-	1	1	7
Froehner/2014 <sup>75</sup>	2131	356 (16.7)	Retrospective	Germany	Prostate	110	Early	All	UVA, MVA	1	1	-	9
Frumovitz/2014 <sup>76</sup>	3086	1026 (33.2)	Retrospective	US	Cervical	133	Early + advanced	S, RT	MVA	1	1	-	9
Gama/2017 <sup>121</sup>	1279	243 (21)	Retrospective	Canada	H&N	30	Early + advanced	RT, S, CT	MVA	1	-	1	6
Genkinger/2015 <sup>77</sup>	1096492	-	Cohort study	US	Pancreas	152.4	-	-	MVA	-	1	-	11

Gong/2007 <sup>78</sup>	752	128 (17)	Retrospective	US	Prostate	116.4	Early + advanced	S / ADT / RT / others	MVA	-	1	-	9
Gong/2012 <sup>70</sup>	510	51 (10)	Retrospective	US	Pancreas	121.2	Early + advanced	All	MVA	1	-	-	9
Goodwin/2012 <sup>79</sup>	535	-	Retrospective	Canada	Breast	145.2	Early	S ± adjuvant CT and/or HT	MVA	1	-	1	9
Grossberg/201680	190	65 (34.2)	Retrospective	US	H&N	68.6	Early	CT + RT	MVA	1	/	1	7
Halabi/2007 <sup>82</sup>	1296	405 (31.2)	Retrospective	US	Prostate (androgen- independent)	33.8	Early + advanced	-	MVA	1	1	-	6
Han/2010 <sup>84</sup>	2511	211 (8.4)	Retrospective	US	Prostate	156	Early	All	UVA	1	-	-	9
Han/2014 <sup>85</sup>	13901	708 (5.09)	Retrospective	US	Various	-	-	-	MVA	-	1	-	5
Xu /2018 <sup>215</sup>	644	92 (14.3)	Retrospective	China	Upper tract urothelial	39	Early	S	MVA	1	1	1	6
He/2012 <sup>86</sup>	1983	546 (27.5)	Retrospective	US	Breast	47.6	Early + advanced	All	MVA	1	-	-	7
Hellmann/2010 <sup>87</sup>	528	76 (14.4)	Prospective	Denmark	Breast	93.6	Early + advanced	-	MVA	1	1	-	10
His/2016 <sup>88</sup>	3160	194 (6.1)	Prospective	France	Breast	109.2	Early	-	MVA	1	1	✓	11
Ho/2012 <sup>89</sup>	1038	337 (32.4)	Retrospective	US	Prostate	41	Early + advanced	S	MVA	-	-	1	6
Houdek/201990	261	71 (8.6)	Retrospective	-	STS	48	-	RT / none	MVA	1	-	1	6
lyengar/2014 <sup>94</sup>	155	30 (19)	Retrospective	US	Tongue	-	Early	S	MVA	1	1	1	5
Izumida/2019 <sup>95</sup>	10824	235 (2)	Cohort study	China	Various	220.8	-	-	MVA	-	1	-	12
Janssen/2015 <sup>96</sup>	927	-	Retrospective	US	Various	-	Early + advanced	-	MVA	1	-	-	5
Jayasekara/2018 <sup>97</sup>	724	164 (22.7)	Cohort study	Australia	CRC	108	Early	-	MVA	1	1	-	11
Jenkins/2018 <sup>98</sup>	502631	12539 (24.9)	Cohort study	UK	Various	93.6	-	-	MVA	1	-	-	7
Jeon/2015 <sup>99</sup>	41021	1632 (4)	Prospective (registry)	Korea	Breast	92	Early	CT, HT	MVA	1	1	-	11
Jiralerspong/2013 <sup>100</sup>	6342	1779 (30)	Retrospective	US	Breast	64.8	Early	-	MVA	1	1	1	7
Kaidar- Person/2015 <sup>101</sup>	184	46 (25)	Retrospective	Israel	CRC	27.6	Advanced	CT, Bevacizumab	MVA	1	-	1	6
Kalb/2019 <sup>102</sup>	612	127 (20.7)	Retrospective	Germany	CRC	58	Early	CT, RT, S	MVA	1	-	1	7
Katzmarzyk/2012 <sup>103</sup>	10522	1972 (19)	Retrospective	Canada	Various	168	Early + advanced	All	MVA	-	1	-	8
Kawai/2016 <sup>104</sup>	20090	897 (4.5)	Prospective (registry)	Japan	Breast	80.4	Early	CT, HT	MVA	1	1	1	10
Keegan/2010 <sup>105</sup>	4153	127 (3)	Retrospective	US	Breast	-	-	-	MVA	1	-	-	5
Keizman/2014 <sup>106</sup>	278	67 (24.1)	Retrospective	Israel	RCC	55	Advanced	TKI	MVA	1	-	1	7
Kelly/2017 <sup>107</sup>	7822	1612 (20.6)	Retrospective	US	Prostate	156	Early + advanced	All	MVA	-	1	-	9
Kenfield/2016 <sup>108</sup>	112185	9984 (8.9)	Prospective	US	Prostate	170	-	-	MVA	-	1	-	12
Khan/2017 <sup>109</sup>	822	- 1	Retrospective	US	Prostate	60	Early + advanced	All	MVA	-	-	1	7
Kichenadasse/2019 <sup>1</sup>	1434	239 (7)	Prospective	Various	NSCLC	-	Advanced	Atezolizumab vs Docetaxel	UVA	1	-	1	7
Kitahara/2014 <sup>111</sup>	313575	9564 (3.04)	Retrospective	Various	Various	-	-	-	MVA	-	1	-	5

Kotsopoulos/2012 <sup>113</sup>	1423	230 (17.5)	Retrospective	Canada	Ovarian	120	Early + advanced	All	MVA	-	1	-	9
Kristensen/2017 <sup>114</sup>	4330	-	Retrospective	Denmark	Endometrial	-	Early + advanced	S	MVA	1	-	-	5
Kwan/2012 <sup>115</sup>	14948	2440 (16.3)	Prospective (cohort)	US	Breast	93.6	Early	S ± adjuvant CT and/or HT and/or RT	MVA	1	1	-	11
Kwan/2013 <sup>116</sup>	11351	3405 (30)	3 pooled case- control, 3 prospective cohort	US	Breast	132	Early + advanced	All	MVA	1	1	-	-
Ladoire/2014 <sup>117</sup>	5009	666 (13.3)	Pooled analysis (2 phase III)	France	Breast	70.8	Early	СТ	MVA	1	-	1	-
Larsen/2015 <sup>118</sup>	1229	167 (14)	Prospective (cohort)	Denmark	Breast	115.2	Early	-	MVA	1	-	-	12
Lee/2010 <sup>120</sup>	2750	120 (4.3)	Retrospective	South Corea	RCC	34.8	Early	S	MVA	-	/	1	6
Leung/2011 <sup>122</sup>	58931	3520 (5.97)	Prospective	Japan	Lung	-	-	-	MVA	-	1	-	7
Li/2009 <sup>123</sup>	841	163 (19.38)	Retrospective	US	Pancreas	-	Early + advanced	-	MVA	1	-	-	5
Lin/2013 <sup>124</sup>	799542	19988 (2.5)	Retrospective	Various	Pancreas	37.2	-	-	MVA	-	1	-	6
Loi/2005 <sup>125</sup>	1101	131 (11.9)	Retrospective	Australia	Breast	60	Early	S / adjuvant	MVA	1	-	1	6
Ma/2008 <sup>126</sup>	2546	87 (3.4)	Retrospective	US	Prostate	84	Early + advanced	-	MVA	1	1	-	7
Maj-Hes/2017 <sup>127</sup>	6519	2462 (37.7)	Retrospective	Austria	Prostate	28	Early	S	MVA	-	-	1	6
Martini/2020128	90	23 (25.5)	Retrospective	US	Various	-	Advanced	IT	MVA	1	-	1	5
Maskarinec/2011 <sup>129</sup>	382	71 (18.5)	Prospective (cohort)	Hawaii	Breast	158.4	Early + advanced	S ± adjuvant CT and/or HT	MVA	1	1	-	12
Mathur/2010 <sup>130</sup>	279	97 (35)	Retrospective	US	Various	31	Advanced	Hepatectomy	MVA	1	-	1	6
Matsuo/2016 <sup>131</sup>	665	459 (69)	Retrospective	US	Uterus	36.4	Early + advanced	S + CTRT	MVA	1	-	1	6
Mazzarella/2013 <sup>133</sup>	1250	101 (8.1)	Retrospective	Europe	Breast	=	Early	S, RT, CT	MVA	1	-	1	5
McCullough/2005 <sup>134</sup>	430236	5433 (1.3)	Prospective	US	Breast	240	Early + advanced	All	MVA	-	1	-	12
McCullough/2016 <sup>135</sup>	1308	301 (23)	Population-based	US	Breast	180	Early	-	MVA	1	1	-	12
McMahon/2017 <sup>83</sup>	1080	-	Retrospective	US	Liver	123.6	Early + advanced	All	MVA	-	1	-	9
McQuade/2019 <sup>136</sup>	1918	513 (26.7)	Pooled analysis	US	Melanoma	=	Advanced	CT, IT, TT	MVA	1	-	1	-
Melhem- Bertrandt/2011 <sup>138</sup>	1413	460 (33)	Retrospective	US	Breast (TN)	59	Early	S ± CT	MVA	1	-	1	7
Meyer/2015 <sup>139</sup>	35703	2,820 (7.9)	Population-based	Switzerland	Various	-	Early + advanced	-	MVA	1	-	-	7
Meyerhardt/2003 <sup>140</sup>	3561	500 (16.8)	Cohort study	US	CRC	112	Early	S + CT	MVA	1	-	1	12
Meyerhardt/2004 <sup>141</sup>	1688	306 (18)	Cohort study	US	CRC	118	Early	S + CT	MVA	1	-	/	12
Meyerhardt/2008 <sup>142</sup>	1043	236 (22.6)	Prospective	US and Canada	CRC	63.6	Early	S / adjuvant	MVA	1	-	1	8
Minlikeeva/2019 <sup>112</sup>	7022	1557 (22.2)	Retrospective (pool data)	US and Australia	Ovarian	-	Early + advanced	-	MVA	1	-	1	5
Moller/2014 <sup>143</sup>	26877	4140 (15)	Cohort study	UK	Prostate	43.2	Early + advanced	-	MVA	-	1	-	11

Montgomery/2007 <sup>144</sup>	1006	160 (16)	Retrospective	US	Prostate (androgen- dependent)	-	Advanced	Bilateral orchiectomy ± Flutamide	MVA	1	-	1	5
Montgomery/2007 <sup>144</sup>	671	253 (38)	Retrospective	US	Prostate (androgen- independent)	-	Advanced	Mitoxantrone/Pred nisone vs Docetaxel/Estram ustine	MVA	1	-	1	5
Morikawa/2011 <sup>145</sup>	1060	200 (19)	Prospective (cohort)	US	CRC	162	Early + advanced	All	MVA	1	1	-	12
Nagle/2018 <sup>148</sup>	1359	568 (41.7)	Retrospective	Australia	Endometrial	85.2	Early + advanced	S±CT	MVA	1	1	-	8
Nakagawa/2016 <sup>149</sup>	1311	25 (1.9)	Retrospective	Japan	NSCLC	59	Early	S	MVA	1	-	1	7
Nechuta/2010 <sup>150</sup>	71243	8264 (11.6)	Cohort study	ÚK	Various	109.2	-	-	MVA	-	1	-	12
Nicholas/2014 <sup>151</sup>	490	203 (41.4)	Retrospective	US	Endometrial	54	Early + advanced	S	MVA	1	-	-	6
Nichols/2009 <sup>152</sup>	3993	639 (16)	Retrospective	US	Breast	76.8	Early	S	MVA	1	1	-	7
Nonemaker/2009 <sup>153</sup>	2054	50 (12.5) / 46 (8.4)	Retrospective	Africa / Europe and America	Lung	-	-	-	MVA	1	1	-	5
Nur/2019 <sup>154</sup>	49259	202 (4.1)	Retrospective	Sweden	Breast	91.6	Early	S	MVA	1	1	-	8
Ogino/2009 <sup>155</sup>	546	84 (16)	Retrospective	US	CRC	-	Early + advanced	-	MVA	1	1	-	5
Oh/2011 <sup>156</sup>	747	251 (33.7)	Cohort study	Korea	Breast	62.2	Early	S ± CT	MVA	-	-	1	10
Olson/2010 <sup>157</sup>	475	108 (23)	Retrospective	US	Pancreas	-	Early + advanced	S	MVA	1	1	-	5
Oudanonh/2019 <sup>158</sup>	3747	1790 (47.8)	Retrospective (registry)	Canada	Breast	-	Early	HT, CT, RT, antiHER2	MVA	1	-	-	5
Pajares/2013 <sup>159</sup>	5683	1376 (24.4)	Retrospective	Spain	Breast	-	Early	CT, HT, S	MVA	1	1	1	5
Parker/2006 <sup>160</sup>	970	336 (34.6)	Retrospective	US	RCC	56.4	Early	S	MVA	1	1	-	7
Parr 2010 <sup>161</sup>	401215	16978 (4.23)	Retrospective	All	Various	-	-	-	MVA	1	-	-	5
Patel/2015 <sup>162</sup>	1174	462 (39.4)	Retrospective	Australia	CRC	-	Advanced	СТ	MVA	1	-	-	5
Pelser/2014 <sup>163</sup>	5727	-	Retrospective	US	CRC	-	Early + advanced	S, RT, CT	MVA	1	1	-	5
Pfeiler/2013 <sup>164</sup>	1509	315 (21)	Retrospective	Austria	Breast	60	Early	-	MVA	1	✓	✓	7
Pierce/2007 <sup>166</sup>	1490	380 (25.5)	Prospective	US	Breast	80.4	Early	S / adjuvant	MVA	1	-	-	8
Potharaju/2018 <sup>167</sup>	392	40 (10.2)	Retrospective	India	GBM	48.6	-	S + RT + TMZ	MVA	1	-	-	6
Previs/2014 <sup>168</sup>	81	28 (34)	Retrospective	US	Ovarian	-	Early + advanced	S, RT	MVA	1	1	1	5
Prizment/2010 <sup>169</sup>	1096	295 (26.9)	Retrospective (registry)	US	CRC	240	Early + advanced	CT, RT, S	MVA	1	1	-	9
Probst- Hensch/2010 <sup>170</sup>	855	72 (19.8)	Retrospective	Switzerland	Breast	43.8	Early	S ± HT	MVA	1	-	-	6
Psutka/2015 <sup>171</sup>	387	166 (43)	Retrospective	US	RCC	86.4	Early	S	MVA	/	1	1	8
Qi/2009 <sup>172</sup>	420	79 (22.7)	Retrospective	US	Lung	-	Advanced	All	MVA	1	-	-	5
Qinchao Hu/201991	576	33 (5,7)	Retrospective	China	H&N	64	Early	S	MVA	-	1	1	7
Roque/2016 <sup>173</sup>	128	72 (56.3)	Retrospective	US	Leiomyosarcom a	49	Early + advanced	All	MVA	1	-	1	6
Rosenberg/2010 <sup>92</sup>	2640	376 (14.24)	Retrospective	Sweden	Breast	-	Early + advanced	S, CT, HT, RT	MVA	-	1	-	5

Rudman/2016 <sup>174</sup>	273	59 (21.6)	Retrospective	UK	Prostate	139.2	Early	HT	MVA	1	1	-	9
Ruterbusch/2014 <sup>93</sup>	627	184 (29)	Retrospective	US	Uterus	-	Early + advanced	S ± CT	MVA	1	1	-	5
Sanchez/2019 <sup>175</sup>	730	249 (34)	Cohort	US	RCC	-	Early + advanced	Systemic therapy + S	MVA	✓	-	-	6
Sasazuki/2011 <sup>176</sup>	353422	7327 (2)	Prospective (cohort)	Japan	Various	150	-	-	MVA	-	1	-	12
Schiffmann/2017 <sup>177</sup>	16014	2403 (15)	Retrospective	Germany	Prostate	36.4	Early	S	MVA	-	-	1	6
Schlesinger/2014 <sup>178</sup>	2143	397 (19)	Prospective	Germany	CRC	42	Early + advanced	-	MVA	1	-	-	6
Seidelin/2016 <sup>179</sup>	3638	984 (27)	Population-based	Denmark	Uterus	-	Early + advanced	-	MVA	1	-	-	7
Senie/1992 <sup>180</sup>	923	207 (22)	Prospective	US	Breast	120	Early	-	MVA	-	-	1	12
Shah/2015 <sup>181</sup>	242	59 (24.5)	Prospective	US	CRC	-	Advanced	S, CT	MVA	/	-	-	7
Shepshelovich/2019 <sup>1</sup>	29217	418 (1.4)	Pooled analysis	Canada	Lung	-	Early + advanced	-	MVA	1	-	-	-
Siegel/2013 <sup>119</sup>	853	216 (25)	Prospective	US	Brain	19	Early	-	MVA	1	-	-	8
Silventoinen/2014 <sup>184</sup>	734438	9187 (1.2)	Retrospective	Finland, Sweden	Various	403.2	-	-	MVA	1	1	-	9
Sinicrope/2012 <sup>185</sup>	2693	630 (23)	Randomized trial	US	CRC	=	Early	S±CT	MVA	1	-	1	5
Sinicrope/2013 <sup>81</sup>	25291	4463 (17,6)	Retrospective	US	CRC	93.6	Early	-	MVA	1	-	1	8
Song/2012 <sup>132</sup>	135745	-	Prospective	Europe	Various	201.6	-	-	MVA	-	1	-	12
Sorbye/2012 <sup>137</sup>	342	67 (19.5)	Retrospective	Europe	CRC	-	Advanced	S ± CT	MVA	-	-	1	
Spangler/2007 <sup>186</sup>	924	286 (31)	Prospective	Various	Prostate	36	Early	S	MVA	-	-	1	10
Sparano/2012 <sup>187</sup>	4817	1745 (46)	Retrospective (phase III)	US	Breast	95	Early	S + CT + HT	MVA	1	1	1	-
Sparano/2012 <sup>188</sup>	6885	2547 (37)	Retrospective (3 phase III)	US	Breast	95	Early	S ± CT ± HT	MVA	1	1	1	9
Spiess/2012 <sup>189</sup>	99	43 (43)	Retrospective	US	RCC	44.4	Early + advanced	S	MVA	1	-	-	6
Spreafico/2017 <sup>190</sup>	564	76 (13)	Retrospective	Canada	Esophagus	32.5	Early + advanced	All	MVA	1	-	1	6
Su/2013 <sup>191</sup>	1030	312 (30.3)	Randomized study	US	Breast	-	Early	S ± CT ± HT	MVA	-	-	1	-
Sun/2015 <sup>192</sup>	1109	410 (37)	Population-based	US	Breast	162	Early	-	MVA	/	1	-	8
Sun/2018 <sup>193</sup>	1017	192 (18.9)	Retrospective	China	Breast	80	Early	CT, HT, RT, S	MVA	1	-	1	8
Sundelof/2009 <sup>194</sup>	580	55 (9.5)	Retrospective	Sweden	Esophagus	-	Early + advanced	-	MVA	1	-	-	5
Taghizadeh/2015 <sup>195</sup>	8645	683 (7.9)	Cohort study	Netherlands	Various	480	-	-	MVA	1	-	-	12
Tait/2014 <sup>196</sup>	501	202 (40.3)	Retrospective	US	Breast	40.1	Early + advanced	S, CT	MVA	1	-	1	6
Thrift/2013 <sup>197</sup>	783	263 (33)	Retrospective	Australia	Esophagus / Gastric	76.8	Early + advanced	S ± CTRT/BSC	MVA	1	-	-	8
Todo/2014 <sup>198</sup>	716	99 (13.8)	Retrospective	Japan	Endometrial	74	Early + advanced	S, CT	MVA	1	1	-	7
Trivers/2005 <sup>200</sup>	1142	156 (4.2)	Retrospective	US	Esophagus / Gastric	-	Early + advanced	S / others	MVA	1	-	1	5
Tsai/2010 <sup>201</sup>	795	103 (13)	Retrospective	US	Pancreatic	-	Early + advanced	S	MVA	1	-	-	5
Tseng/2013 <sup>146</sup>	89056	-	Prospective	Taiwan	Various	144	Early + advanced	All	MVA	-	1	₹.	12
Tseng/2016 <sup>202</sup>	92546	-	Retrospective	Taiwan	Various	204	Early + advanced	All	MVA	-	1	-	9

Turner/2011 <sup>203</sup>	188699	22054 (12.4)	Prospective	US	Lung	312	-	-	MVA	-	1	-	12
Tyler/2012 <sup>204</sup>	425	28 (6.6)	Prospective (case-control)	US	Ovarian	116.4	Early + advanced	All	MVA	1	1	-	12
Valentijn/2013 <sup>205</sup>	10247	1851 (18)	Retrospective	The Netherlands	Various	64.8	-	-	MVA	-	1	-	7
Vidal/2017 <sup>206</sup>	4268	1372 (32.1)	Retrospective	US	Prostate	81.6	Early	S	MVA	-	1	1	8
Wang/2017 <sup>208</sup>	1452	-	Retrospective	China	CRC	40.8	Early + advanced	All	MVA	-	1	-	6
Wang/2019 <sup>209</sup>	250	81 (12)	Retrospective	US	Various	-	Advanced	IT	MVA	1	-	1	5
Warren/2016 <sup>210</sup>	878	-	Retrospective	US	Breast	129.6	Early	S	UVA	-	-	1	9
Widschwendter/2015	3754	788 (21)	Phase III (SUCCESS A)	Germany	Breast	-	Early	CT + HT	MVA	1	i	1	-
Wu/2015 <sup>212</sup>	333	118 (35.4)	Retrospective	US	Prostate	-	Advanced	СТ	MVA	1	-	-	5
Xiao/2014 <sup>213</sup>	5785	1680 (29)	Retrospective	China	Breast	70	Early	CT, HT	MVA	1	-	-	7
Xie/2017 <sup>147</sup>	624	-	Retrospective	China	Lung	63.2	Early	S	MVA	1	-	-	6
Xu/2018 <sup>214</sup>	6197	1885 (30.4)	Cohort study	US	Various	204	-	-	MVA	-	1	-	12
Yang/2008 <sup>216</sup>	635	81 (12.8)	Prospective	Europe	Ovarian	96	Early + advanced	-	MVA	-	1	-	10
Yang/2019 <sup>217</sup>	2442	86 (3.5)	Retrospective	US	HCC	50.5	Early	S	MVA	1	-	1	8
Yano/2013 <sup>218</sup>	3641	792 (21.7)	Prospective	Japan	Various	122	-	-	MVA	-	1	-	12
Yoon/2011 <sup>219</sup>	778	46 (19)	Retrospective	US	Esophagus (adeno)	154.8	Early	S ± adjuvant CT ± RT ± CTRT	MVA	1	1	1	9
Yoon/2015 <sup>220</sup>	2987	417 (13.9)	Retrospective (cohort)	US	Endometrial	-	Early + advanced	S, CT, RT	MVA	1	-	-	5
You/2015 <sup>221</sup>	1314	-	Prospective (cohort)	China	Various	52.7	Early + advanced	-	MVA	1	-	1	10
Yu/1991 <sup>165</sup>	360	44 (12)	Retrospective	US	RCC	53	Early	S	MVA	1	-	-	7
Yuan/2013 <sup>222</sup>	902	136 (15)	Prospective (cohort)	US	Pancreas	480	Early + advanced	-	MVA	1	1	-	12
Zheng/2015 <sup>223</sup>	226	52 (23)	Cohort study	China	CRC	-	Early + advanced	-	MVA	1	-	<b>\</b>	5

<sup>\*</sup>Clinical Trial Randomizing Breast Cancer Patients To Receive BFS Vs Placebo; Patients Received Concomitant Systemic Anticancer Treatment According To Physicians' Decision (Following Institutional Guidelines).

Tab.1: characteristics of included studies

OS, Overall Survival; CSS, Cancer Specific Survival; DFS, Disease-Free Survival; PFS, Progression-Free Survival; DDFI, Distant Disease Free Interval; US, United States Of America; UK, United Kingdom; NSCLC, Non-Small Cell Lung Cancer; HCC, Hepatocellular Carcinoma; RCC, Renal Cell Carcinoma; CRC, Colorectal Cancer; H&N, Head and Neck Tumors; STS, Soft Tissue Sarcoma; SCC, Squamous Cell Carcinoma; GBM, Glioblastoma; TN, Triple Negative; HR, Hormone Receptor; MVA, Multivariate Analysis; UVA, Univariate Analysis; S, Surgery; CT, Chemotherapy; HT, Hormone Therapy; IT, Immunotherapy; TKI, Tyrosine Kinase Inhibitor; TT, Targeted Therapy; TTZ, Trastuzumab; PD-1, Programmed Cell Death 1; PD-L1, Programmed Cell Death Ligand 1; ADT, Androgen Deprivation Therapy; BPS, Bisphosphonate; TMZ, Temozolomide; BCG, Bacillus Calmette-Guérin; RT, Radiotherapy; TURBT, Transurethral Resection of Bladder Tumor; BSC, Best Supportive Care




Fig.1 flow diagram of included studies

Identification

Screening

Eligibility


medRxiv preprint doi: https://doi.org/10.1101/2020.04.28.20082800; this version posted May 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved: No reuse allowed without permission.

Upper Hazard Lower ratio limit limit Z-Value p-Value Abubakar 2018 0,690 2,018 0,605 0,545 Breast pfs 1,180 Ademuyiwa 2011 Breast pfs 0,810 0,490 1,339 -0,822 0,411 Beasley 2012 Breast pfs 0.960 0.770 1.197 -0.363 0.717 Bonn 2014 Prostate pfs 1,110 0.810 1,521 0.649 0.516 Buono 2017 Breast pfs 1,510 0.570 4,000 0.829 0.407 Caan 2008 Breast pfs 1,000 0,700 1,429 0,000 1,000 Cespedes-Feliciano 2017 Breast pfs 0.990 0.750 -0.071 0.943 1.307 Bladder/UTUC Chromecki 2012 pfs 1,160 1.020 1.319 2262 0.024 Clark 2013 1,520 3,667 0,932 0,351 **CRC** pfs 0,630 Copson 2014 Breast 1,210 1,464 0,050 pfs 1,000 1,960 Cortellini 2019 Various pfs 0.720 0.490 1.058 -1.673 0.094 Crozier 2013 **Breast** pfs 1,280 1.050 1,560 2443 0,015 Cullen 2017 Prostate pfs 1,390 0,970 1,992 1,794 0,073 Dahdaleh 2018 CRC pfs 1,670 1,290 2,162 3,893 0,000 pfs 1.020 0.860 0.227 0.820 Dawood 2012 Breast 1.210 Dignam 2003 **Breast** pfs 0.980 0.800 1 201 -0 195 0.845 Dignam 2006 Breast pfs 1,170 0.980 1.397 1.737 0.082 Elwood 2018 Breast pfs 1,300 0,810 2,086 1,087 0,277 Ferro 2018 Bladder/UTUC pfs 2,510 1,760 3,580 5,081 0,000 1,100 Head & Neck 0.413 Gama 2017 pfs 0.700 1.729 0.679 Gong 2007 Prostate pfs 3,610 1,730 7,533 3,420 0,001 Goodwin 2012 1,150 0,850 1,556 0,906 0,365 Breast pfs Grossberg 2016 Head & Neck pfs 0,390 0,150 1,014 -1,931 0,053 pfs Halabi 2007 0,890 0,760 1,042 -1,446 0,148 Prostate His 2016 Breast pfs 0.920 0.570 1,485 -0.341 0,733 Ho 2012 Prostate 1,730 1,120 2,672 2,471 0,013 pfs Houdek 2019 Sarcoma pfs 0,890 0.470 1,685 -0,358 0.721 Hu 2019 Head & Neck pfs 2.016 1.100 3.695 2.268 0.023 Jiralerspong 2013 1682 **Breast** pfs 1 130 0.980 1.303 0.093 Kaidar-Person 2015 CRC pfs 0.940 0.680 1,299 -0.375 0,708 Kawai 2016 Breast pfs 1,150 0,950 1,392 1,434 0,152 Keizman 2014 RCC pfs 0,810 0,530 1,238 -0,974 0,330 Kichenadasse 2019 0.860 0.730 -1.804 0.071 Lung pfs 1.013 Kwan 2012 Breast pfs 1,060 0.940 1,195 0.951 0.342 Ladoire 2014 Breast pfs 1,130 0,930 1,373 1,230 0,219 Lee 2010 RCC pfs 0,215 0,053 0,872 -2,151 0,031 1.500 1.070 Loi 2005 Breast pfs 2.103 2.353 0.019 Maj-Hes 2017 Prostate pfs 2.150 1710 2703 6.552 0000 Mathur 2010 Hepatobiliary pfs 0,900 0.860 0,942 -4,542 0,000 Matsuo 2016 Utherine pfs 1.440 0.860 2.411 1.386 0.166 Mayerhardt 2008 CRC pfs 1.120 0.760 0.573 0.567 1.651 Mazzarella 2013 Breast pfs 1.050 0.730 1.510 0.263 0,792 McQuade 2018 Melanoma pfs 0,790 0,690 0,904 -3,414 0,001 Melhem-Bertrandt 2011 Breast pfs 1,160 0,900 1,495 1,146 0,252 Meyerhardt 2003 CRC pfs 1,240 0,980 1,569 1,792 0,073 CRC Meverhardt 2004 pfs 1.100 0.910 1.330 0.985 0.325 Meverhardt/2008 CRC ďs 1,120 0.780 1.608 0.614 0.539 Ovarian pfs 1,040 0,920 1,176 0,627 0,531 Minlikeeva 2019 Montgomery 2007 Prostate pfs 1,000 0,800 1,250 0,000 1,000 Mutschler 2018 1.380 1.030 1.849 2.158 **Breast** pfs 0.031 Nagakawa 2016 Lung pfs 0.280 0.100 0.784 -2423 0.015 Oh 2011 Breast pfs 1,020 0,505 2,060 0,055 0,956 Pajares 2013 Breast pfs 1,130 0,980 1,303 1,682 0,093 Pfeiler 2013 **Breast** pfs 1,450 1,030 2,041 2,129 0,033 1.470 Previs 2014 Ovarian pfs 0.080 27,011 0.259 0.795 Psutka 2015 **RCC** pfs 1,090 0.740 1,606 0,436 0,663 Utherine 0,660 0,370 -1,407 Roque 2016 pfs 1,177 0,159 Schiffmann 2017 Prostate pfs 0,980 0,860 -0,303 0,762 1.117 Senie 1992 pfs 1.290 1.000 1.960 Breast 1.664 0.050 Sinicrope 2012 CRC pfs 1,370 1,140 1,646 3.357 0.001 Sinicrope 2013 CRC pfs 1,060 1,000 1,124 1,960 0,050 Sorbye 2012 CRC pfs 1,040 0,750 1,442 0,235 0,814 1.790 3.484 Spandler 2007 Prostate pfs 1.290 2.484 0.000 Sparano 2012 Breast pfs 1,170 1.040 1,316 2613 0.009 Sparano 2012 (2) Breast 1,240 1,080 1,424 3,052 0,002 pfs 2,322 Spreafico 2017 Gastroesophageal pfs 1,620 1,130 2,625 0,009 Su 2013 pfs 1,000 0,740 1,351 0,000 1,000 **Breast** Sun 2018 **Breast** pfs 1880 1 280 2761 3219 0.001 Tait 2014 Breast pfs 0.945 0.605 1,476 -0.249 0.804 Vidal 2017 Prostate pfs 1,110 0.940 1.311 1.230 0.219 Vidal 2018 Prostate pfs 1,060 0,840 1,338 0,491 0,623 CRC 0.610 -2.596 Wang 2019 pfs 0.420 0.886 0.009 Warren 2016 Breast pfs 1.440 0.970 2.138 1.809 0.070 Widschwendter 2015 1,380 0,760 2,506 1,058 0,290 Breast pfs Xu 2018 Bladder/UTUC pfs 1,060 0,780 1,441 0,372 0,710 Yang 2019 1.030 1.666 2.201 Hepatobiliary pfs 1.310 0.028 Yoon 2011 Breast pfs 1,210 0.960 1.525 1.614 0,106 You 2015 CRC pfs 1,030 0,730 1,453 0,168 0,866 Yu 1991 **RCC** pfs 0,430 0,190 0,973 -2,025 0,043 Zheng 2015 CRC pfs 1.590 1.140 2.218 2.732 0.006 1.136 1.079 1.195 4887 0.000 0.01 0,1 10

name	vas not certified l	н	azard Lowe radio limit	r Upper t ilmit	Z-Value	p-Value		_		Hazard ratio and 9	5% CI_
I-Rahman 2019 namson 2006 akar 2018	Lung Breast Breast	06 06 06	0,780 0,6 1,480 1,0 1,180 0,8	90 2,010	-3,972 2,512 0,862	0,000 0,012 0,389				<b>┸</b> ⅃ᡓ	<u>-</u>
uylwa 2011 2017	Breast Breast	06 06	0,940 0,5 0,540 0,2	40 1,636 60 1,122	-0,219 -1,652	0,827 0,098					_
sh 2013 Salinas 2014	Lung Breast	06 06	0,920 0,6 1,790 1,1	50 2.786	-0,568 2,579	0,570				<del></del>	<del>-</del>
2013 018 era 2015	Utherine Hepatobillary Ovarian	06 06	1,950 1,5 0,930 0,8 0,680 0,4	00 2,535 20 1,055 30 1,075	4,989 -1,130 -1,649	0,000 0,259 0,099				<del></del> =	
ley 2012 2014	Breast Prostate	06 06	0,860 0,7 1,470 1,0	00 1,057 30 2,098	-1,436 2,123	0,151 0,034				<del></del>	-
2013 waite 2010	CRC Breast	06 06	1,260 0,8 1,290 0,7	80 1,804 00 2,377	1,262 0,816	0,207 0,414				_ <del> </del>	<u> </u>
0 2017 2008 Ibell 2015	Breast Breast CRC	06 06	1,250 0,3 1,300 0,8 1,300 1,1	00 2.113	0,328 1,059 5,310	0,743 0,290 0,000			•	- 15	
2018 Hini 2016	Hepatobillary Breast	06 06 06	0,840 0,5 1,080 0,9	20 1,357	-0,713 1,734	0,476 0,083				<del></del>	
edes Feliciano 2017 g 2000	CRC Breast	06 06	2,540 1,7 1,340 0,8	10 3,773 80 2,040	4,617 1,364	0,000 0,173				<del>  -</del>	
2010 neckl 2012 g 2017	Breast Bladder/UTUC Breast	06 06 06	1,550 1,1 1,080 0,9 1,270 0,9	70 1,202	2,505 1,404 1,360	0,012 0,160 0,174				<u> </u>	<b>-</b>
2013 Hand 2011	CRC Breast	06	1,770 0,5 2,490 1,5	90 5,310	1,019 3,931	0,308					<u> </u>
or 2016 by 2011	Breast Breast	06 06 06	1,540 1,0 1,540 1,2	70 2,216 30 1,928	2,324 3,765	0,020					
on 2014 Illni 2019 aleh 2018	Breast Various CRC	06 06 06	1,350 1,0 0,500 0,3 1,750 1,2	80 1,688 20 0,781 20 2,510	2,636 -3,044 3,040	0,008 0,002 0,002			-	<b>─</b> ──   <sup>-</sup>	-
taso 2008 2012	Breast Pancreas	06 06	1,750 1,2 1,290 0,9 2,680 1,2	90 1,681	1,886 2,405	0,059 0,016				⊢ <del>≡</del>	<u> </u>
ood 2012 am 2003	Breast Breast	06 06	0,970 0,8 1,310 1,1	10 1,162 20 1,532	-0,331 3,377	0,741 0,001				+-	. –
m 2006 m 2006	Breast CRC	06 06	1,170 0,9 1,190 1,0	40 1,456 00 1,416	1,405 1,960	0,160 0,050				[書]	_
Rose 2006 thiou 2008	CRC Prostate Breast	06 06	1,500 1,0 1,000 0,7 0,940 0,6	50 1,333	1,960 0,000	0,050 1,000 0.695				_£	_
od 2018 is 2009 2018	Breast Prostate	06 06 06	0,940 0,6 1,470 1,0 1,090 0,8	80 2,001	-0,392 2,449 0,789	0,014 0,430					-
io 2014 ner 2014	CRC Prostate	06 06	1,320 1,1 1,470 1,1	20 1,556 00 1,964	3,312 2,604	0,001 0,009				T 🚍	<u> </u>
Mtz 2014 2017	Utherine Head & Neck	06 06	1,260 1,1 0,790 0,5	00 1,443 00 1,248	3,336 -1,010	0,001 0,312				<del></del>	_
2012 Win 2012 Sberg 2016	Pancreas Breast Head & Neck	06 06 06	1,280 0,9 1,190 0,8 0,300 0,1	90 1,591	1,418 1,174 -3,404	0,156 0,241 0,001				‡	-
iologi 2016 ii 2007 ii010	Prostate Prostate	06 06 06	0,800 0,6 1,160 0,8	80 0,941	-3,404 -2,691 0,839	0,001 0,007 0,402					_
012 1900 2010	Breast Breast	06 06	0,735 0,5 1,610 1,1	60 0,965 20 2,314	2,219 2,572	0,026 0,010				- <del>-</del> - -	■—
D16 2018	Breast ∀arlous	06 06	1,050 0,5 0,480 0.3	50 2,005 90 0,591	0,148 -6,928	0,882					
s 2017 sen 2015 sekara 2018	Gastroesophageal Varlous CRC	06 06 06	0,870 0,5 1,046 0,5 1,140 0,8	80 1,305 40 2,025 20 1,585	-0,673 0,133 0,779	0,501 0,894 0,436					
ns 2018 2015	∨arlous Breast	06 06	1,460 1,3 1,290 1,1	30 1,603 30 1,473	7,953 3,769	0,000				T	
rspong 2013 rr-Person 2015	Breast CRC	06 06	1,240 1,0 0,620 0,3	40 1,478 30 1,165	2,397 -1,486	0,017 0,137			-		· 
2019 N 2016 an 2010	CRC Breast Breast	06 06 06	0,930 0,4 1,460 1,1 1,210 1,0	60 1,880 60 1,838	-0,202 3,225 1,960	0,840 0,001 0,050					F
man 2014 enadasse 2019	RCC Lung	06 06	0,890 0,5 0,780 0,6	40 1,467 00 1,014	-0,457 -1,856	0,648 0,063					
ara 2014 mik 2017	Various CRC	06 06	2,570 2,1 1,690 1,0	40 3,086 00 2,856	10,104 1,960	0,000					
nsen 2017 12012	Utherine Breast	06 06	1,220 1,0 1,170 1,0	40 1,316	2,177 2,613	0,030					
12013 re 2014	Breast Breast Breast	06 06	1,140 1,0 1,270 0,9	80 1.646	2,022 1,807 2,341	0,043 0,071 0,019				<u> </u>	_
n 2015 018 19	Gastroesophageal Pancreas	06 06 06	1,430 1,0 0,770 0,5 1,860 1,3	60 1,929 10 1,163 50 2,563	-1,243 3,795	0,214				<b>─</b> ■┼ <u>-</u>	_
105 N 2020	Breast ∀arfous	06 06	1,480 0,9 0,540 0,2 2,060 1,2	90 2,213 50 1,166 30 3,450	1,911 -1,568 2,747	0,056				╼	<del>-</del>
artnec 2011 ir 2010 io 2016	Breast Hepatobillary	06 06	0,960 0,9	20 1,002	2,747 -1,880 0,523	0,006 0,060 0,601				<b></b> _	
rhardt 2008 arella 2013	Officer Office	06 06 06	1,190 0,6 0,885 0,5 1,450 0,9	75 1,362	-0,555 1,680	0,579				<b>-</b>	_
illough 2016 iade 2018	Breast Melanoma	06 06	1,360 1,0 0,740 0,6	80 1,713 30 0,869	2,614 -3,667	0,009					<del>-</del>
eman 2018 em-Bertrandt 2011	Breast Breast	06 06	1,410 1,2 1,250 0,9	50 1,645	7,571 1,594	0,000				<del>│</del> <u>╼</u> ▛	<u>-</u>
r2015 r2015 r2015	Bladder/UTUC Breast CRC	06 06 06	1,160 0,6 1,070 0,6 1,300 0,8	40 1,789	0,464 0,258 1,280	0,642 0,796 0.200					=
r2015 r2015	Gastroecophageal Head & Neck	06 06	1,450 0,7 0,780 0,4	10 2,961	1,020 -0,787	0,308					
r2015 r2015	Hepatobillary Lung	06 06	2,210 1,1 0,800 0,5	80 4,139 70 1,123	2,477 -1,290	0,013				<del>-</del> -	
r2015 r2015 r2015	Pancreas Prostate Utherine	06 06 06	1,600 0,9 1,540 0,9 1,880 1,1	30 2,550	1,698 1,678 2,309	0,090 0,093 0,021				<del> </del>	
r 2015 r 2015 rhardt 2003	Various CRC	06 06	1,880 1,1 1,080 0,8 1,340 1.0	00 1,458	0,503 2,549	0,021 0,615 0.011				-	
rhardt 2004 rhardt/2008	CRC CRC	06 06	1,090 0,9 0,945 0,5	00 1,320 75 1,553	0,882 -0,223	0,378 0,823					<u>-</u>
eeva 2019 Jomery 2007	Ovarian Prostate	06 06	1,160 1,0 0,900 0,7	20 1,125	3,602 -0,925	0,000 0,355				- <b>==</b> -	
awa 2012 shier 2018 kawa 2016	CRC Breast Lung	06 06 06	1,170 0,9 1,460 1,0 0,480 0,1	20 2,090	1,340 2,068 -1,386	0,180 0,039 0,166					-
2018 das 2014	Otherine Otherine	06 06	1,210 0,8 1,400 0,8	80 1,664 60 2,279	1,173 1,353	0,241				- +=	<u>-</u>
ds 2009 019	Breast Breast	06 06	1,520 1,1 1,630 1,1	70 1,975 20 2,372	3,136 2,552	0,002 0,011				<i>_</i> =	<b>5</b>
2009 12010 nonh 2019	CRC Pancreas Breast	06 06 06	1,170 0,4 1,230 0,8 1,480 1,1	40 3,111 90 1,700 30 1,938	0,315 1,254 2,848	0,753 0,210 0,004				15.	
rek 2018 er 2006	Lung RCC	06 06	1,280 0,6 0,720 0,5	20 2,643 70 0,909	0,667 -2,756	0,504 0,006				_ <del></del>	_
2010 2015	Various CRC	06 06 06	0,970 0,9	10 1,034 80 1,301	-0,935 0,678	0,350 0,498				₩.	_
res 2013 r 2014 r 2013	Breast CRC Breast	06 06 06	1,140 0,7 1,190 1,0 1,810 1,1	20 1,388	0,576 2,212 2,423	0,565 0,027 0,015				1=	
r2013 2007 raju 2018	Breast Breast Brain	06 06 06	1,420 0,8 0,680 0,4	70 2,318 70 0,984	1,403	0,015 0,161 0,041					
2014 ent 2010	Ovarlan CRC	06 06	2,080 0,9 1,460 1,1	30 4,652 50 1,854	1,783 3,108	0,075				_ <del>    _</del>	-
Hensch 2010 a 2015	Breast RCC	06 06	1,040 0,4 1,250 0,8	70 2,301 70 1,796	1,207	0,923 0,228					
19 2016 an 2016	Lung Utherine Prostate	06 06	0,780 0,5 0,580 0,3 1,060 0,7	40 0,989	-1,644 -1,999 0,275	0,100 0,046 0,783					_
susch 2014 singer 2014	Utherine CRC	06 06 06	1,100 0,8 0,840 0,6	30 1,458 20 1,138	0,663 -1,125	0,507 0,260					
In 2016 I 2017	Utherine Lung	06 06	1,120 0,9 0,800 0,6	40 1,334 70 0,955	1,268 -2,466	0,205 0,014				<u>-</u> -	
2015 shelovich 2019	CRC Lung	06 06	1,090 0,7 0,960 0,8	10 1,673 80 1,047	0,394 -0,920	0,694 0,358				<b>-</b>	_
2013 ope 2012 ope 2013	Brain CRC CRC	06 06 06	1,320 1,0 1,340 1,1 1,100 1,0	40 1,675 20 1,603 40 1,163	2,282 3,198 3,330	0,022 0,001 0,001					=
no 2012 no 2012 (2)	Breast Breast	06 06	1,230 1,0 1,400 1,1	80 1,401 50 1,704	3,120 3,353	0,002 0,001				<u> </u>	<b>-</b>
s 2012 floo 2017	RCC Gastroesophageal	06 06	0,420 0,2 2,630 1,8	20 0,802 10 3,821	-2,629 5,072	0,009				<del>-</del>	
of 2008 015	Gastroesophageal Breast	06 06	0,970 0,6	60 1,426 40 1,467	-0,155 0,734	0,877 0,463				-	
018 radieh 2015 radieh 2015	Breast Breast CRC	06 06	2,050 1,2 1,520 0,8 1,280 0,7	80 2,625	2,891 1,502 0,862	0,004 0,133 0,389				_ <del></del> _	
adeh 2015 adeh 2015 adeh 2015	CRC Lung Prostate	06 06 06	1,280 0,7 0,780 0,4 3,330 1,3		0,862 -0,961 2,527	0,389 0,336 0,011					
2015 114 2012	Prostate Breast Gastroesophageal	06 06 06	0,865 0,5	10 8,465 50 1,360 40 1,470	2,527 -0,628 -0,144	0,011 0,530 0,886				<del></del> _	
2014 s 2005	Utherine Gastroesophageal	06 06	0,880 0,5 0,830 0,6	10 1,518 40 1,076	-0,459 -1,405	0,646 0,160					-
2010 2012	Pancreas Ovarian	06 06	0,730 0,5 0,900 0,6	60 0,952 00 1,350	-2,327 -0,509	0,020 0,611					
2018 2017	Prostate CRC CRC	06 06	0,790 0,6 1,540 1,1	50 0,960 20 2,118	-2,369 2,657 -1,980	0,018 0,008					■—
2019 chwendter 2015 015	CRC Breast Prostate	06 06 06	0,590 0,3 1,440 0,7 0,670 0,3	90 2,625	-1,980 1,190 -0,995	0,048 0,234 0,320			_		—
2014 017	Breast Lung	06 06	1,006 0,7 2,870 1,4	80 1,297 80 5,565	0,046 3,120	0,963 0,002			_		
)18 2019	Bladder/UTUC Hepatobillary	06 06	1,110 0,7 1,410 1,0	80 1,580 80 1,841	0,580 2,526	0,562 0,012					_ _
2013 2011 2015	∨artous Breast Utherine	06 06	1,180 0,7 1,110 0,8 0,780 0,4	70 1,416	0,676 0,840 -0,885	0,499 0,401 0,376					_
2015 015 91	Otherine CRC RCC	06 06 06	0,780 0,4 1,470 0,0 0,680 0,3	80 27,011	-0,885 0,259 -1,299	0,795		+			
					1,451	0,194					

Study name	Subgroup within study	Outcome		Statist	tics for eac	h studv		Hazard ratio and 95% CI
	<u> </u>		Hazard	Lower	Upper			
Abdullah 2011	Various	css	ratio 1,030	limit 1,010	limit 1,050	<b>Z-Value</b> 2,955	<b>p-Value</b> 0,003	
Akinyemiju 2018	Various	CSS	0,760	0,610	0,947	-2,447	0,014	<del>-=</del> -
Alsaker 2011 Arem 2013	Breast Utherine	CSS CSS	1,520 1,790	1,250 1,200	1,848 2,670	4,196 2,854	0,000 0,004	
Bandera 2015 Barroso 2017	Ovarian Various	CSS CSS	0,670 3,550	0,400 0,530	1,122 23,778	-1,522 1,306	0,128 0,192	_ <del></del>
Bassett 2011	Prostate	css	1,520	0,890	2,596	1,533	0,125	<del>  -</del> -
Beasley 2012 Blair 2019	Breast Breast	CSS	0,720 1,330	0,610 0,950	0,850 1,862	-3,884 1,661	0,000 0,097	
Boggs 2011	Various	CSS	1,120	0,860	1,459	0,841	0,400	<u>+=_</u>
Bonn 2014 Boyle 2013	Prostate CRC	CSS	1,290 1,330	0,670 0,890	2,484 1,988	0,762 1,391	0,446 0,164	
Braithwaite 2010 Caan 2008	Breast Breast	CSS CSS	0,720 1,200	0,340 0,700	1,525 2,057	-0,858 0,663	0,391 0,507	
Campbell 2015	CRC	CSS	1,200	1,060	1,358	2,881	0,004	<del> </del>
Cespedes Feliciano 2017 Cespedes-Feliciano 2017	CRC Breast	CSS	2,290 1,010	1,350 0,790	3,885 1,291	3,073 0,079	0,002 0,937	<del>  _</del>
Chen 2010	Breast	css	1,440	1,020	2,033	2,073	0,038	
Chromecki 2012 Chung 2017	Bladder/UTUC Breast	CSS CSS	1,260 1,200	1,100 0,750	1,443 1,920	3,336 0,760	0,001 0,447	<del>  -</del>
Cleveland 2011 Connor 2016	Breast Breast	CSS CSS	1,220 0,970	0,510 0,570	2,918 1,651	0,447 -0,112	0,655 0,911	
Conroy 2011	Breast	CSS	1,450	1,050	2,002	2,256	0,024	
Dal Maso 2008 Dickerman 2017	Breast Prostate	CSS	1,380 1,090	1,020 0,760	1,867 1,563	2,088 0,468	0,037 0,640	
Dignam 2003	Breast	CSS	1,200	0,970	1,485	1,679	0,093	
Dignam 2006 Dignam 2006	Breast CRC	CSS CSS	1,070 1,220	0,820 0,980	1,396 1,519	0,498 1,779	0,618 0,075	
Doria-Rose 2006	CRC	css	1,500	0,900	2,500	1,556	0,120	<del>  _=</del>
Drake 2017 Efstathiou 2008	Various Prostate	CSS CSS	1,450 1,640	1,170 1,010	1,797 2,663	3,394 2,000	0,001 0,045	
Elwood 2018 Emaus 2009	Breast Breast	CSS CSS	0,980 1,430	0,690 1,010	1,392 2,025	-0,113 2,016	0,910 0,044	
Eskelinen 2017	RCC	CSS	1,020	0,770	1,351	0,138	0,890	<del>   </del>
Farris 2018 Fedirko 2014	Prostate CRC	CSS	1,130 1,260	0,800 1,040	1,596 1,527	0,694 2,361	0,488 0,018	<del>   </del>
Frumovitz 2014	Utherine	CSS	1,240	1,060	1,451	2,688	0,007	<del>  -</del> _
Genkinger 2015 Gong 2007	Pancreas Prostate	CSS CSS	1,480 2,640	1,270 1,180	1,725 5,906	5,021 2,363	0,000 0,018	<del>*</del>
Grossberg 2016	Head & Neck	CSS	0,260	0,110	0,615	-3,069	0,002	<del></del>
Halabi 2007 Han 2014	Prostate Breast	CSS CSS	0,810 1,240	0,680 0,940	0,965 1,636	-2,361 1,522	0,018 0,128	
Han 2014 Hellmann 2010	Various Breast	CSS	1,290 1,820	0,980 1,110	1,698 2,984	1,816	0,069 0,018	<del> </del>
His 2016	Breast	CSS CSS	1,720	0,790	3,745	2,374 1,366	0,018	
Hu 2019 Hynes 2017	Head & Neck Gastroesophageal	CSS CSS	2,022 0,890	1,040 0,570	3,931 1,390	2,076 -0,513	0,038 0,608	
lyengar 2014	Head & Neck	CSS	5,010	1,690	14,852	2,906	0,004	
Izumida 2019 Jayasekara 2018	Various CRC	CSS CSS	2,720 1,410	1,340 0,900	5,521 2,209	2,770 1,500	0,006 0,134	
Jeon 2015	Breast	CSS	1,210	1,020	1,435	2,187	0,029	<del>  _</del>
Jiralerspong 2013 Katzmarzyk 2012	Breast Various	CSS	1,230 1,490	1,000 1,190	1,513 1,866	1,960 3,476	0,050 0,001	<del>                                </del>
Kawai 2016	Breast	CSS	1,470	1,110	1,947	2,688	0,007	- <del></del> -
Kelly 2017 Kenfield 2016	Prostate Prostate	CSS CSS	1,460 1,070	1,020 0,818	2,090 1,400	2,068 0,493	0,039 0,622	
Khan 2017	Prostate	CSS	1,400	0,990	1,980	1,903	0,057	_ <del></del> _
Kocarnik 2017 Kotsopoulos 2012	CRC Ovarian	CSS CSS	1,860 1,110	0,670 0,870	5,164 1,416	1,191 0,840	0,234 0,401	
Kwan 2012 Kwan 2013	Breast Breast	CSS CSS	1,100 1,100	0,950 0,970	1,274 1,247	1,274 1,485	0,203 0,137	
Landman 2008	Various	CSS	0,570	0,320	1,015	-1,908	0,056	
Lee 2018 Leung 2010	Gastroesophageal Lung	CSS CSS	0,750 0.550	0,440 0,100	1,278 3,025	-1,057 -0,687	0,290 0,492	
Lin 2013	Pancreas	CSS	0,960	0,670	1,376	-0,222	0,824	
Liss 2016 Ma 2008	RCC Prostate	CSS CSS	2,840 1,950	1,290 1,170	6,252 3,250	2,592 2,562	0,010 0,010	
Maskarinec 2011	Breast	css	2,990	1,220	7,328	2,395	0,017	
Matsuo 2018 McCullough 2005	Utherine Breast	CSS CSS	0,220 1,470	0,060 1,130	0,807 1,912	-2,284 2,871	0,022 0,004	- <b>-</b>
McCullough 2016 McMahon 2017	Breast Hepatobiliary	CSS CSS	1,630 0,790	1,150 0,500	2,310 1,248	2,745 -1,010	0,006 0,312	
McTieman 2018	Breast	CSS	1,350	1,240	1,470	6,920	0,000	-   -
Moller 2014 Morikawa 2012	Prostate CRC	CSS	1,270 1,100	0,900 0,810	1,792 1,494	1,360 0,610	0,174 0,542	<del>  -</del>
Murakami 2018	Bladder/UTUC	CSS	3,460	1,380	8,675	2,647	0,008	_ [
Nagle 2018 Nechuta 2010	Utherine Various	CSS CSS	0,840 0,820	0,560 0,620	1,260 1,085	-0,843 -1,391	0,399 0,164	
Nichols 2009	Breast	CSS	1,420	0,860	2,345	1,370	0,171	<del>+=</del>
Nonemaker 2009 Nur 2019	Lung Breast	CSS CSS	0,500 1,450	0,160 0,810	1,563 2,596	-1,192 1,251	0,233 0,211	
Ogino 2009 Oudanonh 2019	CRC Breast	CSS CSS	1,100 1,330	0,240 0,910	5,042 1,944	0,123 1,473	0,902 0,141	
Pajares 2013	Breast	CSS	1,130	0,940	1,358	1,301	0,193	_ <del> </del>
Parker 2006 Pelser 2014	RCC CRC	CSS CSS	0,480 1,150	0,360 0,960	0,640 1,378	-5,000 1,517	0,000 0,129	<del></del>
Previs 2014	Ovarian	CSS	1,660	0,570	4,834	0,929	0,353	
Prizment 2010 Psutka 2015	CRC RCC	CSS CSS	1,300 1,310	0,950 0,800	1,779 2,145	1,639 1,073	0,101 0,283	
Rosenberg 2009	Breast	CSS	1,400	1,100	1,782	2,735	0,006	<u> </u>
Rudman 2016 Ruterbusch 2014	Prostate Utherine	CSS CSS	1,020 0,900	0,550 0,580	1,892 1,397	0,063 -0,470	0,950 0,638	
Sasazuki 2011	Various	CSS	1,250	1,070	1,460	2,813	0,005	<del>  _</del>
Silventoinen 2014 Sparano 2012 (2)	Various Breast	CSS CSS	1,540 1,450	1,270 1,160	1,867 1,813	4,390 3,264	0,000 0,001	
Sun 2015 Todo 2014	Breast	CSS	0,970	0,680	1,384	-0,168	0,867	_ <del></del> _
Tseng 2013	Utherine Various	CSS CSS	0,880 0,830	0,510 0,730	1,518 0,944	-0,459 -2,845	0,646 0,004	
Tseng 2016 Turner 2011	Various Lung	CSS	1,012 0,540	0,918 0,270	1,116 1,080	0,240 -1,742	0,810 0,081	<del></del>
Valentijn 2013	Various	CSS CSS	0,630	0,460	0,863	-2,879	0,004	<del>-</del>
Vidal 2017 Vidal 2018	Prostate Prostate	CSS CSS	2,050 1,110	1,040 0,860	4,041 1,433	2,073 0,802	0,038 0,423	
Wang 2017	CRC	CSS	1,510	1,080	2,111	2,410	0,016	
Xu 2018 Xu 2018	Bladder/UTUC Various	CSS CSS	1,130 1,150	0,770 0,970	1,658 1,363	0,624 1,609	0,532 0,108	
Yang 2008	Ovarian	CSS	1,230	0,870	1,739	1,172	0,241	<del> <u>-</u>-</del>
Yoon 2011 Yuan 2013	Breast Pancreas	CSS CSS	1,140 1,280	0,880 1,060	1,477 1,546	0,992 2,566	0,321 0,010	
			1,179	1,125	1,236	6,856	0,000	<u> </u>
								0,01 0,1 1 1 10



Suppl. file 2: Funnel plot of publication bias for overall survival analysis